PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29206806-1 2018 BACKGROUND: Various immunoassays have been used for cyclosporine A (CsA) analysis in human whole blood; however, they could not fully satisfy the requirements of criteria for accuracy and specificity in CsA measurement. Cyclosporine 52-66 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 68-71 29193016-2 2018 Ciclosporin A (CsA) is a widely used, potent immunosuppressant but it is not effective in all patients with atopic dermatitis, and side-effects limit its use. Cyclosporine 15-18 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 0-13 29387331-4 2018 In patients who fail first-line therapy after approximately 3-5 days of intravenous steroids, medical rescue therapy is indicated with either infliximab (IFX) or cyclosporine (CsA). Cyclosporine 162-174 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 176-179 29237963-1 2017 BACKGROUND: Trough cyclosporine (CsA) blood level can influence incidence of graft-versus-host disease (GVHD) and relapse in patients with acute leukemia undergoing allogeneic hematopoietic stem cell transplant (HSCT). Cyclosporine 19-31 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 33-36 28569378-1 2017 Cyclosporine A (CsA) is an immunosuppressive drug commonly used in organ transplant patients to prevent allograft rejections. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 29381954-1 2017 BACKGROUND: Cyclosporine (CsA) is one of the immunosuppressive drugs, whose pharmacokinetic characteristics vary greatly among individuals. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 28439923-1 2017 RATIONALE: In the determination of immunosuppressive drugs cyclosporine A (CSA), tacrolimus (TARO), sirolimus (SIRO), and everolimus (EVE) in whole blood there is an open debate about which is the best assay between immunochemistry and liquid chromatography/tandem mass spectrometry (LC/MS/MS). Cyclosporine 59-73 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 75-78 28516402-1 2017 Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. Cyclosporine 37-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 28405602-11 2017 Patients with twice daily cyclosporine A (CSA) formulation needed longer to finish the 4-TTMT than patients with the once-daily tacrolimus formulation. Cyclosporine 26-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 27567631-1 2017 Cyclosporine A (CsA) induces hypertension after transplantation. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 27620209-0 2016 In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy. Cyclosporine 69-72 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 54-67 28353583-1 2017 The objective of the present study was to assess the effect of cyclosporine (CsA) on the pharmacokinetic parameters of mycophenolic acid (MPA), an active mycophenolate mofetil (MMF) metabolite, and to compare with the effect of everolimus (EVR).Anonymized medical records of 404 kidney recipients were reviewed. Cyclosporine 63-75 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 77-80 27620209-3 2016 Whether immunosuppression with mycophenolate mofetil (MMF) or Ciclosporin A (CsA) influences the cytotoxic effect of CIK cell immunotherapy is still an open issue. Cyclosporine 77-80 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-75 27052254-1 2016 INTRODUCTION: Cyclosporine (CsA) is an effective agent for treating patients with acute steroid-refractory ulcerative colitis (UC). Cyclosporine 14-26 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 28-31 27283486-1 2016 Cyclosporin A (CsA) and dipyridamole (DPy) are potent inhibitors of the P-glycoprotein (P-gp; ABCB1) in vitro. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 25270396-2 2015 Elevated fibroblast growth factor (FGF)-23 in cyclosporine A (CsA) users with SLE are associated with decreased active vitamin D and osteocalcin. Cyclosporine 46-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-65 27266681-1 2016 OBJECTIVE: To assess the effectiveness and safety of the conversion therapy from traditional cyclosporine (CsA) triple immunosuppression therapy to sirolimus (SRL) combined with low dose CsA and prednisone (Pred) in renal transplantation recipients in a five-year follow-up period. Cyclosporine 93-105 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 107-110 26794875-1 2016 In the present work, the feasibility of cyclosporine A lipid nanoparticles (CsA LN) for oral administration was investigated. Cyclosporine 40-54 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 76-79 27374283-1 2016 Cyclosporine (CSA), which is one of the substrates of ATP binding cassette subfamily B member 1 (ABCB1), is widely used as an immunosuppressant in patients undergoing transplantation. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 27747732-1 2015 A 26-year-old woman developed symptoms of acute toxicity during cyclosporine (CsA) therapy for graft-versus-host disease prophylaxis. Cyclosporine 64-76 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 78-81 26057330-1 2015 PURPOSE: To investigate the regulation of matrix metalloproteinase (MMP)-3 and MMP-13 expression over time and in the presence of cyclosporine A (CsA) in primary cultured human pterygium fibroblasts. Cyclosporine 130-144 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 146-149 25835315-1 2015 OBJECTIVES: We retrospectively examined how the cyclosporine-A (CSA) microemulsion administration mode affected blood CSA levels, as well as how the dose and blood levels of CSA affected its therapeutic effect against systemic lupus erythematosus (SLE). Cyclosporine 48-62 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 64-67 25536542-3 2015 Conflicting results arise from the literature, particularly as concerns cyclosporine (CsA). Cyclosporine 72-84 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 86-89 27496445-1 2016 BACKGROUND: Cyclosporine (CsA) is an immunosuppressive agent whose use is associated with adverse effects, including nephrotoxicity. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 25775018-1 2015 Cyclosporin A (CSA) suppresses immune function by blocking the cyclophilin A and calcineurin/NFAT signaling pathways. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 25357076-2 2015 One of the most promising immunomodulatory substances whose immunosuppressive effect has revolutionized solid organ transplantation is cyclosporine (CsA). Cyclosporine 135-147 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 149-152 24890314-2 2014 In this retrospective cohort study, we analyzed biomarkers of the immunosuppressive effects of cyclosporine A (CSA) by quantifying nuclear factor of activated T cells (NFAT)-regulated gene expression during telaprevir (TVR) therapy in 5 liver transplant patients. Cyclosporine 95-109 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 111-114 26087670-2 2015 Immunosuppressive therapy with cyclosporine (CSA) is often successful in reducing proteinuria, but its use is associated with a high relapse rate. Cyclosporine 31-43 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 45-48 24983307-1 2015 BACKGROUND: Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. Cyclosporine 27-41 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 43-46 24486136-1 2014 Mycophenolic acid (MPA) is an immunosuppressant used in transplant rejection, often in combination with cyclosporine (CsA) and tacrolimus (Tac). Cyclosporine 104-116 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 118-121 24344232-1 2014 AIMS: Topical ciclosporin A (CsA) is a therapeutic option for dry eye disease (DED) to control ocular surface inflammation and improve tear function. Cyclosporine 29-32 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-27 24751518-1 2014 Cyclosporine A (CsA) is an immunosuppressive drug that targets cyclophilins, cellular cofactors that regulate the immune system. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 24786238-4 2014 Cyclosporine (CsA) is an immunosuppressant that is highly effective for severe disease, but its mechanism in AD skin lesions has not been studied. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 24142471-8 2014 Drug-induced gingival overgrowth was the single most common type of lesion, and its prevalence was significantly higher for patients using cyclosporine A (CSA; 29%) versus patients using tacrolimus (TAC; 5%, P = 0.007); the prevalence was even higher with the simultaneous use of calcium channel blockers and CSA (47%) or TAC (8%, P = 0.002). Cyclosporine 139-153 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 155-158 24375637-3 2014 Here we report that cyclosporin A (CsA) can inhibit HBV entry into cultured hepatocytes. Cyclosporine 20-33 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 35-38 24942911-1 2014 BACKGROUND/AIMS: Cyclosporine (CsA) is a calcineurin inhibitor widely used as an immunosuppressant in organ transplantation. Cyclosporine 17-29 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 31-34 24497284-5 2014 RESULTS: Mass spectra of CsA obtained upon post-column addition of solutions of Ca(II), Cu(II) and Zn(II) showed complexes between cyclosporin and the metal, including [2CsA + Me](2+) and [CsA-H + Me](+). Cyclosporine 131-142 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 25-28 24142471-8 2014 Drug-induced gingival overgrowth was the single most common type of lesion, and its prevalence was significantly higher for patients using cyclosporine A (CSA; 29%) versus patients using tacrolimus (TAC; 5%, P = 0.007); the prevalence was even higher with the simultaneous use of calcium channel blockers and CSA (47%) or TAC (8%, P = 0.002). Cyclosporine 139-153 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 309-312 23953553-1 2013 BACKGROUND: The aim of this study was to demonstrate noninferiority of everolimus with reduced cyclosporine (CsA) vs mycophenolate mofetil (MMF) with reduced CsA in improving renal function. Cyclosporine 95-107 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 109-112 23521314-1 2013 AIMS: Ciclosporin A (CsA) dosing in immunosuppression after paediatric kidney transplantation remains challenging, and appropriate target CsA exposures (AUCs) are controversial. Cyclosporine 21-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 6-19 24250211-1 2013 We report that one 18-year-old female patient with no epilepsia history developed severe epileptiform seizures while she was receiving "ciclosporin A (CsA)-mycophenolate-methylprednisolone" antirejection therapy after combining one week"s voriconazole administration following allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndromes (MDS). Cyclosporine 136-149 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 151-154 23981724-1 2013 Clinical immunosuppression protocols use calcineurin inhibitors, such as cyclosporine A (CsA) or tacrolimus (FK506), or mammalian target of rapamycin (mTOR) inhibitors, such as sirolimus (rapamycin). Cyclosporine 73-87 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 89-92 23258544-2 2013 Transplant patients treated with immunosuppressant drugs such as cyclosporine A (CsA), an inhibitor of calcineurin phosphatase, frequently develop similar metabolic complications. Cyclosporine 65-79 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 23519664-1 2013 Cyclophilins belong to a family of proteins that bind to the immunosuppressive drug cyclosporin A (CsA). Cyclosporine 84-97 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 99-102 23121663-4 2013 STUDY DESIGN AND METHODS: We hereby report two patients with a history of relapsed idiopathic TTP, who both received cyclosporin A (CSA) as a prophylactic manner after the remission was achieved. Cyclosporine 117-130 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 132-135 23755756-1 2013 The aim of this work is to compare the results of a commercially available liquid chromatography tandem mass spectrometry (LC-MS/MS) method in a clinical pathology laboratory for routine Therapeutic Drug Monitoring (TDM) of cyclosporine (CsA) and tacrolimus (Tacr) in pediatric patients with those obtained with the current antibody-conjugated magnetic immunoassay (ACMIA). Cyclosporine 224-236 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 238-241 23248028-4 2013 Recently, the results were published from a National Institutes of Health (NIH)-sponsored multicenter randomized trial comparing cyclosporine (CSA) with a combination of mycophenolate mofetil (MMF) and pulse dexamethasone (DEX) for the treatment of steroid-resistant FSGS. Cyclosporine 129-141 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 143-146 22821730-1 2013 Cyclosporine A (CSA), but not tacrolimus (TAC), inhibits hepatitis C virus (HCV) replication in vitro. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 23106694-1 2013 Cyclosporine (CSA) is an immunosuppressant used for the prevention of graft rejection and graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 22972132-5 2012 Topical cyclosporine A (CsA) may improve AKC signs and symptoms, and be used as a corticosteroid sparing agent. Cyclosporine 8-22 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 24-27 22974004-1 2012 Cyclosporine (CSA) is the most commonly used medication for GVHD prophylaxis. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 23555748-1 2013 The aim of this study was to investigate whether hATMSCs protect against cyclosporine (CsA)-induced renal injury. Cyclosporine 73-85 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 23144461-3 2012 It has been observed that cyclosporin A (CsA) treatment, particularly in transplant patients, may sometimes be linked to the development of TTP. Cyclosporine 26-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 22970897-3 2012 This study describes the accuracy and precision of ciclosporin (CsA) strength when compounded as capsules (10 and 300 mg) and solutions (50 and 150 mg/mL). Cyclosporine 51-62 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 64-67 21240873-1 2011 INTRODUCTION: The aim of the study was to compare efficacy of cyclosporine (CsA) very low exposure with everolimus high exposure, with respect to CsA standard exposure with enteric-coated mycophenolate sodium (EC-MPS) therapy. Cyclosporine 62-74 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 76-79 23573469-1 2012 BACKGROUND: Although the immunosuppressant cyclosporine (CsA) is widely used after kidney transplantation over the long term, there is still no firm consensus on the best way to monitor of CsA blood levels. Cyclosporine 43-55 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 57-60 23573469-2 2012 OBJECTIVES: Cyclosporine (CsA) assay is critical for the management of renal transplant recipients due to inter- and intra-patient variation in CsA absorption and metabolism. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 23573469-2 2012 OBJECTIVES: Cyclosporine (CsA) assay is critical for the management of renal transplant recipients due to inter- and intra-patient variation in CsA absorption and metabolism. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 144-147 22225545-4 2012 In the present study, we examined the effect of cyclosporine A (CsA), a PPIase inhibitor, on SIV replication. Cyclosporine 48-62 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 64-67 22089787-1 2011 A 12-year-old girl with a history of steroid and cyclosporine (CsA) resistant nephrotic syndrome owing to focal and segmental glomerulosclerosis (FSGS) has progressed to end-stage renal disease (ESRD) for which she underwent hemodialysis for 18 months before she successfully received a fully matched kidney transplant from her sister at the age of nine years. Cyclosporine 49-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 63-66 21653632-1 2011 Renal magnesium (Mg(2+)) and sodium (Na(+)) loss are well-known side effects of cyclosporine (CsA) treatment in humans, but the underlying mechanisms still remain unclear. Cyclosporine 80-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 23060930-1 2012 Calcineurin inhibitors (CNIs) such as cyclosporin A (CSA) and tacrolimus (FK506) are efficacious in patients with steroid-refractory or steroid-dependent ulcerative colitis (UC). Cyclosporine 38-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 22466612-2 2012 Cockayne syndrome is a related disorder with defective TCR and consists of two complementation groups, Cockayne syndrome (CS)-A and CS-B, which are caused by mutations in ERCC8 (CSA) and ERCC6 (CSB), respectively. Cyclosporine 178-181 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 171-176 22546085-2 2012 Cyclosporin A (CsA), an immunosuppressive agent that targets the nuclear factor pathway of activated T-cells (NF-AT) to bind cellular cyclophilins (CyP), dose-dependently inhibited FIPV replication in vitro. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 21438096-1 2012 BACKGROUND: Cyclosporine (CsA) or infliximab (IFX) are used as rescue therapies in steroid-refractory, severe attacks of ulcerative colitis (UC). Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 22132303-1 2012 Measurements of Cyclosporine (CsA) systemic exposure permit its dose adjustment in allogenic stem cell transplantation recipients to prevent graft-versus-host disease. Cyclosporine 16-28 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 30-33 21996945-3 2011 This retrospective study analyzes the effectiveness of combined systemic acyclovir and immunosuppressive therapy with cyclosporine A (CSA) or mycophenolate mofetil (MMF) after high-risk keratoplasty in herpetic keratitis. Cyclosporine 118-132 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 134-137 21839257-1 2011 OBJECTIVE: The pharmacokinetics of cyclosporine (CsA) depend on numerous factors over the transplantation course. Cyclosporine 35-47 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 22016592-2 2011 We studied the regulation of hepatic albumin synthesis by cyclosporin A (CsA) in Huh7 cells. Cyclosporine 58-71 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 73-76 21716180-6 2011 Malignancy occurred in 5.2% of patients on cyclosporine (CSA), azathioprine (AZA) and prednisone (P); in 3.4% of patients on mofetil mycophenolate (MMF) with CSA and P; in 3.3% of patients on MMF with tacrolimus (TAC) and P; and in 2 of 20 patients (10%) receiving AZA with P 15 years after transplantation. Cyclosporine 43-55 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 57-60 20368718-1 2011 Cyclosporine (CsA) is a substrate of cytochrome P450 (CYP) 3A5 and has a narrow therapeutic range with large inter-individual variability. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 21333626-1 2011 Cyclosporine A (CsA) is an immunosuppressive drug commonly used for maintaining chronic immune suppression in organ transplant recipients. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 21446974-2 2011 The vasoconstrictor impact of cyclosporine (CsA) and to a lesser extent tacrolimus, in both acute and chronic settings, results from a decrease in vasodilators and increase in vasconconstrictors while direct tubular toxicity results from blockade of mitochondrial permeability transition pores and inhibition of prolyl isomerase. Cyclosporine 30-42 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 44-47 20540636-12 2010 It was inversely correlated with cyclosporine A (CsA) level (r = -0.499, p = 0.035). Cyclosporine 33-47 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 21624207-1 2011 OBJECTIVE: To systematically evaluate the clinical effects of cyclosporine A (CsA) and tacrolimus, which are calcineurin inhibitors, on lupus nephritis. Cyclosporine 62-76 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 78-81 21760716-1 2011 PURPOSE: To investigate the role of postoperative topical 0.05% cyclosporine A (CsA) eye drops (Restasis( ), Allergan Pharmaceutical) in the prevention of recurrence among patients with primary pterygium treated with bare-sclera technique. Cyclosporine 64-78 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 80-83 21244763-1 2010 Cyclosporine A (CsA) effectively controls psoriasis, however, its long-term continuous use is not recommended. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 20588203-1 2010 BACKGROUND: Whether the loss-of-function allele CYP3A5*3 variant is associated with significantly impaired metabolism of cyclosporine A (CsA) in transplant patients is still controversial because of the lack of prospective, large-scale clinical studies performed among diversely ethnic populations. Cyclosporine 121-135 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 137-140 20458598-6 2010 The immunosuppressive regimen for the second transplantation consisted of tacrolimus and prednisolone; cyclosporine (CsA), mycophenolate mofetil, and prednisolone had been used for the first transplantation. Cyclosporine 103-115 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 117-120 21166111-2 2010 After cyclosporine A (CsA) microemulsion administration, effective renal plasma flow (ERPF) and glomerular filtration rate(GFR) are decreased coincident with the maximal concentration (Cmax) of CsA. Cyclosporine 6-20 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 22-25 21166111-2 2010 After cyclosporine A (CsA) microemulsion administration, effective renal plasma flow (ERPF) and glomerular filtration rate(GFR) are decreased coincident with the maximal concentration (Cmax) of CsA. Cyclosporine 6-20 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 194-197 20726688-5 2010 Amongst the last is the calcineurin inhibitor (CNI) (cyclosporine A (CsA) and tacrolimus)-related nephrotoxicity. Cyclosporine 53-67 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 69-72 20883533-1 2010 Cyclosporin A (CsA), rapamycin (Rapa) and mycophenolic acid (MPA) are frequently used for GVHD prophylaxis and treatment after allogeneic stem cell transplantation (SCT). Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 20519340-1 2010 The aim of this study was to investigate the potential of calcineurin inhibitors [cyclosporine A (CsA) and tacrolimus (Tac)] to inhibit cellular uptake of atorvastatin mediated by the liver-specific organic anion-transporting polypeptide 1B1 (OATP1B1) in vitro. Cyclosporine 82-96 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 98-101 20542069-1 2010 Cyclosporin A (CsA) is an immunosuppressive drug. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 21122398-1 2010 OBJECTIVE: To explore the efficiency and side-effects of the combination of cyclosporine A (CsA) and thalidomide in patients with myelodysplastic syndromes (MDS). Cyclosporine 76-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 20361354-3 2010 Cyclosporine A (CsA) is a potent immunosuppressive agent which prevents allograft rejection in organ transplantation and various immunological diseases. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 20614016-1 2010 BACKGROUND: Cyclosporin A (CsA) has important anti-microbial activity against parasites of the genus Leishmania, suggesting CsA-binding cyclophilins (CyPs) as potential drug targets. Cyclosporine 12-25 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 27-30 20614016-1 2010 BACKGROUND: Cyclosporin A (CsA) has important anti-microbial activity against parasites of the genus Leishmania, suggesting CsA-binding cyclophilins (CyPs) as potential drug targets. Cyclosporine 12-25 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 124-127 20352119-3 2010 The immunosuppressant, cyclosporine A (CsA) has potent anti-HCV activity towards both HCV replicons and the genotype 2a cell culture infectious virus. Cyclosporine 23-37 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 39-42 20439767-3 2010 The method, which involves making thermodynamic measurements of protein-folding reactions in complex biological mixtures to detect protein-drug interactions, is demonstrated in an experiment to identify yeast protein targets of the immunosuppressive drug, cyclosporin A (CsA). Cyclosporine 256-269 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 271-274 20548907-1 2010 BACKGROUND: Patients with severe atopic dermatitis (AD) can benefit from cyclosporin (CSA) treatment. Cyclosporine 73-84 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 86-89 20427863-1 2010 Several generic cyclosporine (CsA) formulations have been developed over the last decade and are now widely available. Cyclosporine 16-28 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 30-33 19404248-2 2009 There was considerable interindividual variation in the inhibitory effects of cyclosporine (CSA), tacrolimus (TAC), and prednisolone (PRD) but only a small amount of interindividual variation for mycophenolic acid (MPA). Cyclosporine 78-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 21448533-3 2010 Cyclosporin (CsA) is a rare cause of PC, scarcely reported in the literature, and should be considered in the differential diagnosis of ICH and papilledema in those patients. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 20145520-1 2010 BACKGROUND: The effect of cyclosporine A (CsA) on polyomavirus BK virus (BKV) replication remains unclear. Cyclosporine 26-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 20652037-2 2010 Close therapeutic drug monitoring of Cyclosporine (CsA) in transplant outpatients is a favourable procedure to maintain the long-term blood drug levels within their respective narrow therapeutic ranges. Cyclosporine 37-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 19617341-3 2009 We have previously demonstrated P-gp activity at the human BBB using PET of (11)C-verapamil distribution into the brain in the absence and presence of the P-gp inhibitor cyclosporine-A (CsA). Cyclosporine 170-184 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 186-189 19481021-3 2009 However, these first-line statins possess a rather modest lipid-lowering effect and selection of alternative statins is limited due to interactions with cyclosporine (CsA). Cyclosporine 153-165 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 167-170 19386625-2 2009 A physiologically realistic EHC model was proposed to estimate and assess the impact of cyclosporine (CsA) dose on the extent of EHC of MPA and MPAG. Cyclosporine 88-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 19458944-1 2009 BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse. Cyclosporine 48-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-65 19458944-1 2009 BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse. Cyclosporine 48-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 134-137 19458944-1 2009 BACKGROUND: Trough- or 2-h post-dose (C2) blood cyclosporine (CsA) concentrations are used for prediction of efficacy and toxicity of CsA in transplant recipients concomitantly treated with antiproliferative agents, but information on utility of blood CsA levels in patients treated with proliferation signal inhibitors (PSIs), such as everolimus, is sparse. Cyclosporine 48-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 134-137 19460557-2 2009 BACKGROUND: Cyclosporine (CsA) renal toxicity is a well-known side effect. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 18486150-3 2009 We have proposed that cyclosporin A (CsA), despite being a calcineurin inhibitor, will activate PKC in B cells, thus promoting Epstein-Barr virus (EBV)-induced transformation. Cyclosporine 22-35 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-40 19066978-1 2009 Cyclosporine (CsA) treatment in immunoglobulin A nephropathy (IgAN) is controversial and has not been widely studied. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 19376366-1 2009 Immunosuppressive drugs, such as tacrolimus (FK506) and cyclosporine (CsA), play an essential role in graft survival, preventing rejection. Cyclosporine 56-68 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 70-73 18716711-2 2009 METHODS: One-hundred and seventy-four cyclosporin (CsA)-treated renal transplant recipients were studied. Cyclosporine 38-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 19218792-3 2009 Here we hypothesized that the immunosuppressant ciclosporin A (CsA), known for its profibrotic side effect, promotes myofibroblast differentiation of BMDC in the postischemic kidney. Cyclosporine 63-66 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 48-61 19779801-1 2009 Cyclosporine A (CsA) is a well-characterized anti-HCV reagent. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 19249558-1 2009 We have reported that cyclosporine (CsA) has direct effect to promote Epstein-Barr virus (EBV) transformation of human peripheral blood B lymphocytes. Cyclosporine 22-34 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 36-39 18471799-1 2008 Cyclosporin A (CsA), an immunosuppressive drug, has overgrowth effects on human gingival fibroblasts (HGF) in vitro. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 19799203-1 2009 AIM: Evaluation of cyclosporine (CSA) withdrawal safety and efficacy in children late after kidney transplantation. Cyclosporine 19-31 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 33-36 18694850-3 2008 In the present review we have focused our attention on the possible role of cyclosporine A (CsA), anti-Tumour Necrosis Factor (TNF) alpha agents in the treatment of HIV or HCV infected autoimmune patients. Cyclosporine 76-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 18929851-2 2008 Among the immunosuppressants, cyclosporine (CsA) can induce neurological side effects. Cyclosporine 30-42 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 44-47 18656538-3 2008 Since clinical studies are elaborate, we sought a way to predict the kinetic behaviour of a propylene glycol solution of CsA (CsA-PG) and a liposomal formulation (L-CsA). Cyclosporine 121-124 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 126-132 18817870-1 2008 Calcineurin inhibitors (CNI) cyclosporine (Csa) and tacrolimus (Tac) are now first intention immunosuppressive drugs in renal transplantation. Cyclosporine 29-41 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 43-46 18971855-1 2008 AIM: To study the efficacy and safety of topical ciclosporin A (CsA) as an adjunctive therapy after surgical treatment of primary pterygium including excision and limbal conjunctival autograft (LCA) with respect to postoperative pain and complications. Cyclosporine 64-67 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-62 18448056-2 2008 cyclosporine (CsA) has proved effective in controlling acute attacks of ulcerative colitis unresponsive to IV steroids. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 18628650-1 2008 A major side effect of the powerful immunosuppressive drug cyclosporine (CsA) is the development of a chronic nephrotoxicity whose mechanisms are not fully understood. Cyclosporine 59-71 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 73-76 18720690-1 2008 The prevailing notion in dermatology is that mycophenolate mofetil (MMF) is safer than cyclosporine (CsA), but that CsA has greater efficacy. Cyclosporine 87-99 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 101-104 17922928-1 2008 Cyclophilins are target molecules for cyclosporin A (CsA), an immunosuppressive antimicrobial drug. Cyclosporine 38-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 18030500-1 2008 The aim of our study was to investigate the effect of tangerine juice on the pharmacokinetics of cyclosporine A (CsA), in children who had received a renal transplant. Cyclosporine 97-111 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 113-116 19246887-2 2008 We aimed to assess the benefit of the combination of antithymocyte globulin (ATG) and cyclosporine (CsA). Cyclosporine 86-98 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 100-103 18089380-1 2007 Sometimes intravenous administration of cyclosporine (CsA) is essential before oral administration is possible. Cyclosporine 40-52 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 54-57 18040888-5 2008 More importantly, metformin, together with the PTP classical inhibitor cyclosporin A (CsA), strongly mitigated the activation of this apoptotic cascade. Cyclosporine 71-84 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 86-89 18089382-1 2007 BACKGROUND: Cyclosporine (CsA) 2-hour postdose (C2) monitoring is recommended to assess CsA exposure and predict clinical outcomes among heart transplant recipients. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 18089382-1 2007 BACKGROUND: Cyclosporine (CsA) 2-hour postdose (C2) monitoring is recommended to assess CsA exposure and predict clinical outcomes among heart transplant recipients. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 88-91 17724614-1 2007 Cyclosporin A (CsA) is an immunosuppressant with severe side effects including gingival overgrowth. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 17504846-2 2007 The present retrospective study investigated 86 children with SRNS due to FSGS and MCNS and found improved rates of complete remission in children with idiopathic FSGS and MCNS after combination therapies using ciclosporin A (CSA) and prednisolone (PRED). Cyclosporine 211-224 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 226-229 18064802-1 2007 The calcineurin inhibitors cyclosporine (CsA) and tacrolimus (Tac) are widely used in the prevention of acute rejection after solid organ transplantation. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 17911470-4 2007 Cyclosporin A (CsA) is an immunosuppressive agent used to treat a wide range of ADs, but there is a large evidences in the literature, both in vitro and in vivo, suggesting that CsA also exerts an inhibitory effect on HCV replication at standard therapeutic dose. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 17911470-4 2007 Cyclosporin A (CsA) is an immunosuppressive agent used to treat a wide range of ADs, but there is a large evidences in the literature, both in vitro and in vivo, suggesting that CsA also exerts an inhibitory effect on HCV replication at standard therapeutic dose. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 178-181 17889206-2 2007 The objective of this study was to prospectively assess the impact of conversion from cyclosporine (CsA) to tacrolimus on lung function in patients who developed BOS while receiving CsA-based immunosuppressive therapy. Cyclosporine 86-98 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 100-103 17614361-1 2007 For lung transplant patients, a respirable, inulin-based solid dispersion containing cyclosporine A (CsA) has been developed. Cyclosporine 85-99 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 101-104 17362315-1 2007 The purpose of this study was to estimate the response rate of 26-h continuous infusion cyclosporine A (CSA) combined with carboplatin (CBDCA) and subcutaneous alpha-interferon (IFN), in recurrent ovarian cancer (OC), and to measure their effects on CBDCA pharmacokinetics. Cyclosporine 88-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 17542337-1 2007 AIMS: Single daily dose cyclosporine (SDD-CsA) might be a new option providing comparable efficacy, increased compliance and less nephrotoxicity compared to standard twice-daily dose cyclosporine (TDD-CsA). Cyclosporine 24-36 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 17542337-5 2007 13 patients were treated primarily with single daily dose cyclosporine (pSDD-CsA). Cyclosporine 58-70 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 77-80 17322623-1 2007 BACKGROUND: Cyclosporine (CsA), Mycophenolate mofetil (MMF) and prednisolone (PSL) are widely used for the prevention of acute rejection after heart transplantation. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 17127700-1 2007 BACKGROUND: Renal outcome after ciclosporin (CsA) is not clear in most studies involving patients with many renal comorbid conditions. Cyclosporine 32-43 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 45-48 17264526-3 2007 Under immunosuppressive treatment with cyclosporine A (CSA) the patient developed early-onset (day +33) and ultimately fatal leukoencephalopathy. Cyclosporine 39-53 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 55-58 17161467-1 2007 Cyclosporine A (CSA) has various biological effects on T cells, including inhibition of interleukin (IL)-15-induced IL-17 production in CD4+ T cells from patients with rheumatoid arthritis (RA). Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 17304156-1 2007 Cyclosporine A (CsA) is an immunosuppressive drug widely used in pediatric renal graft recipients. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 17274875-4 2006 The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA. Cyclosporine 86-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 17389782-2 2007 Ciclosporin A (CsA) is used in resistant cases, but also as a first-line treatment, due to the serious side effects of cytotoxic drugs. Cyclosporine 15-18 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 0-13 17464771-1 2007 Cyclosporin A (CSA) and tacrolimus (FK506) are two common immunosuppressive agents used post blood and marrow transplantation. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 17181650-1 2007 The proliferation signal inhibitor everolimus (Certican), has demonstrated efficacy with full-dose cyclosporine (CsA) (Neoral). Cyclosporine 99-111 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 113-116 17175300-1 2006 A recent report noted that cyclosporine (CsA) inhibits replication of the hepatitis C virus (HCV) in vitro. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 17101321-3 2006 Cyclosporine A (CsA) specifically inhibits HCV replication through blocking the viral RNA polymerase enzyme NS5B. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 17038001-3 2006 Multivariate analysis identified previous immunosuppressive therapy with antithymocyte-globulin (ATG) and ciclosporin (CsA) as a risk factor for graft rejection (relative risk: 16.6, P = 0.001). Cyclosporine 106-117 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 119-122 16998264-1 2006 BACKGROUND: The purpose of this study was to characterize the pharmacokinetics of cyclosporine (CsA) in Japanese heart transplant patients, and to optimise the monitoring strategy based on measurements of the area under the curve of plasma concentration absorption phase or 2 h post-dose concentrations (C(2)). Cyclosporine 82-94 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 96-99 17045935-1 2006 BACKGROUND: Monitoring of the 2-hour post-dose sample (C(2)) for cyclosporine (CsA) has gained favor; however, choosing a single-point surrogate marker of therapeutic effect for a drug with extensive pharmacokinetic variability is problematic and has limitations. Cyclosporine 65-77 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 79-82 17032751-1 2006 Cyclosporin A (CsA), a calcineurin inhibitor, has been widely used as an immunosuppressant, and is known to induce hyperlipidemia and dyslipoproteinemia with low levels of high-density lipoprotein (HDL). Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 16858688-1 2006 Cyclosporine (CsA) causes a dose-related decrease in renal function in experimental animals and humans. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 16980025-3 2006 Glucocorticoids are well documented to cause bone loss, but the role of cyclosporine (CsA) remains controversial, especially among long-term recipients on low doses of steroid. Cyclosporine 72-84 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 86-89 16716758-1 2006 BACKGROUND & AIMS: Cyclosporine (CSA) has been shown to be effective in steroid-refractory ulcerative colitis (UC) and as an alternative to glucocorticosteroids in patients with severe attacks of UC. Cyclosporine 23-35 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-40 16778365-1 2006 Long-term treatment of childhood nephrotic syndrome (NS) and rheumatic diseases with cyclosporine A (CsA) given as a single daily dose may yield better results and allow safer use of the drug than the conventional twice-daily dosing. Cyclosporine 85-99 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 101-104 16778365-4 2006 The initial daily dose of CsA (Neoral) was 2.0 mg/kg, given as a single daily dose before breakfast. Cyclosporine 31-37 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 16723476-1 2006 PURPOSE: To determine the feasibility, safety, and effectiveness of an episcleral or deep scleral lamellar sustained release cyclosporine (CsA) device in a naturally occurring animal model of uveitis. Cyclosporine 125-137 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 139-142 16722827-1 2006 AIMS: St John"s wort (SJW) decreases the blood concentration of ciclosporin A (CsA), which may result in allograft rejection. Cyclosporine 79-82 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 64-77 16704434-2 2006 Response rates with horse anti-thymocyte globulin (h-ATG) plus ciclosporin (CsA) are about 60-70%, and robust responders have an excellent long-term survival. Cyclosporine 63-74 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 76-79 16757288-2 2006 We describe the effect of the coadministration of Amprenavir/Ritonavir (APV/r) and FosAmprenavir (FosAPV) on cyclosporine (CsA) concentrations in two patients receiving OLT for end-stage liver disease due to hepatitis C Virus. Cyclosporine 109-121 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 123-126 16730566-1 2006 BACKGROUND: Inadequate cyclosporine (CsA) blood levels are a major risk factor for acute rejection in transplant recipients. Cyclosporine 23-35 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-40 16541194-1 2006 The effects of berberine (BBR) on the pharmacokinetics of ciclosporin A (CsA) were examined in healthy volunteers. Cyclosporine 58-71 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 73-76 16652084-1 2006 Cyclosporine (CSA) is a widely used immunosuppressive agent, predominantly for transplant patients. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 16647511-2 2006 Several reports have linked cyclosporine (CsA) with this alteration. Cyclosporine 28-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 16640530-1 2006 Use of C(2) monitoring for cyclosporine A (CsA) microemulsion results in improved clinical outcomes vs. trough (C(0)) monitoring. Cyclosporine 27-41 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 43-46 17124044-5 2006 For patients treated with immunosuppressive therapy (IST), antithymocyte globulin (ATG) and cyclosporin (CSA) remain the standard regimen with excellent overall survival but less impressive failure-free survival due to nonresponse, relapse and later clonal disorders. Cyclosporine 92-103 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 105-108 16972021-1 2006 The monitoring of the blood concentration at 2 h (C(2)) after the oral administration of a cyclosporine (CsA) microemulsion was reconfirmed to be useful for the prediction of systemic exposure, the area under the blood concentration-time curve from 0 to 4 h (AUC(0-4)), in a group of Japanese patients, consisting of 33 children aged 5-15 years and 19 young adults aged 16-27 years, with a greater correlation for C(2) (r = 0.927) than the trough concentration (r = 0.488). Cyclosporine 91-103 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 105-108 17717968-1 2006 Cyclosporine (CsA), a member of the family of calcineurin inhibitors, is a cornerstone of the immunosuppressive treatments used after organ transplantation. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 16495873-2 2006 Patients who undergo a renal transplant also require a pharmacological immunosuppressor therapy with cyclosporine (CsA) as well as anti-hypertensive calcium channel-blockers (CCBs); the former suppresses interferon and interleukin-2 production thus interfering with T cell cell-mediated activity, while the latter are used in order to counteract the nephrotoxicity of CsA which causes the local release, of thromboxane A2 with vascular vasoconstriction in the kidney. Cyclosporine 101-113 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 115-118 16898534-1 2006 Cyclosporin A (CsA) is an immunosuppressive agent used in children for the treatment of steroid-dependent idiopathic nephrotic syndrome (INS). Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 16898486-16 2006 During MMF therapy Csa treatment could be reduced from a mean CsA dose 4.3 to 2.9 mg/kg/24 hours (p=0.008). Cyclosporine 62-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 19-22 16107580-1 2005 Cyclosporine A (CsA) and tacrolimus have been associated with an increased risk for diabetes after transplantation, whereas sirolimus is deemed to be devoid of any effect on glucose metabolism. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 16386613-1 2005 Despite two decades of use, there are limited data on the best way to monitor Cyclosporine (CsA) for heart transplantation. Cyclosporine 78-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 16271221-1 2005 OBJECTIVE: To evaluate the safety and reliability of cyclosporine microemulsion (CsA-ME) C(2) monitoring and to determine the target level of C(2) in Chinese adult liver transplant recipients. Cyclosporine 53-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 16298579-1 2005 Cyclosporine A (CsA) is one of the keystones in immunosuppressive treatment after solid organ transplantation, despite its major side effects such as nephrotoxicity. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 16164223-1 2005 Cyclosporin A(CsA) and tacrolimus (FK506) are important immunosuppressants to inhibit rejection of transplanted organs and to treat various immunological disorders, however those drugs produce major side effects. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 16120063-1 2005 BACKGROUND: Controversy remains about the interaction between mycophenolate mofetil (MMF) and the calcineurin inhibitors cyclosporin (CsA) and tacrolimus (TACR). Cyclosporine 121-132 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 134-137 15840681-1 2005 BACKGROUND: Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C(2)) as the best single time-point predictor of the extent of CsA exposure and as the optimal basis for monitoring immunosuppressive therapy in renal transplant patients. Cyclosporine 50-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 63-66 15840681-1 2005 BACKGROUND: Recent developments have proposed the cyclosporin (CsA) concentration at 2 h post-dose (C(2)) as the best single time-point predictor of the extent of CsA exposure and as the optimal basis for monitoring immunosuppressive therapy in renal transplant patients. Cyclosporine 50-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 163-166 15880019-2 2005 These effects have been confirmed by clinical studies in which everolimus demonstrated comparable efficacy to azathioprine and mycophenolate mofetil in heart and renal transplantation, respectively, when combined with full-dose cyclosporine (CsA; Neoral). Cyclosporine 228-240 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 242-245 15877794-1 2005 Profiling of absorption of cyclosporine (CsA) microemulsion is a concept in therapeutic drug monitoring (TDM) designed to optimize the clinical benefits of the drug in transplant recipients. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 16004552-1 2005 The immunosuppressive drugs cyclosporin (CsA) and tacrolimus (Tac) are widely used to prevent acute rejection following solid-organ transplantation. Cyclosporine 28-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 15914972-1 2005 BACKGROUND: Cyclosporine A (CsA) causes distal renal tubular acidosis (RTA) and osteoporosis. Cyclosporine 12-26 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 28-31 15880022-4 2005 RESULTS: The first case study demonstrates that stable graft function can be achieved in an "old-for-old" kidney transplant patient, who receives everolimus in combination with reduced-exposure cyclosporine (CsA). Cyclosporine 194-206 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 208-211 15726383-1 2005 BACKGROUND: Cyclosporine (CsA) is a widely used drug in the treatment of posterior uveitis. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 15919482-2 2005 CASE REPORT: Two years after heart transplantation with ATG induction, cyclosporine (CsA; trough levels of 250 ng/mL)-based triple drug immunosuppression), a 23-year-old patient developed a small round lesion within the left lateral liver segment. Cyclosporine 71-83 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 85-88 15919451-1 2005 The narrow therapeutic window of the immunosuppressive drug cyclosporine (CsA), the interindividual variability of its metabolism, and the immunosuppressive activity/toxicity of some metabolites require investigation to correlate the parent substance and its metabolites and observed clinical parameters. Cyclosporine 60-72 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 74-77 15946914-3 2005 In the first week only a few patients achieved the suggested C2 levels (19% > 1500, 50% > 1200 ng/ml) despite an increased cyclosporine (CsA) dose. Cyclosporine 129-141 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 143-146 15748638-4 2005 For example, solid organ transplant patients have elevated rates of skin cancer that are correlated with the dose and length of exposure to immunosuppressive drugs (predominantly cyclosporine A (CsA) and ascomycin (FK506)-related tacrolimus). Cyclosporine 179-193 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 195-198 15864171-1 2005 OBJECTIVE: The efficacy of intravenous cyclosporin (CSA) in acute severe ulcerative colitis (UC) is well established. Cyclosporine 39-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 15919494-2 2005 Cyclosporine (CsA)-related thrombotic microangiopathy (TMA) was observed in 15 (3.3%) patients. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 15516239-1 2004 BACKGROUND: Cyclosporine (CsA) is a widely used immunosuppressive agent in kidney transplant patients. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 15730912-3 2005 Cyclosporine A (CsA), which is routinely used to prevent the allograft rejection, is reported to have the inhibitory activity on hepatitis B virus (HBV) replication in vitro. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 15852743-1 2005 OBJECTIVE: To evaluate the effect of cyclosporine (CSA) on serum magnesium and its fractional excretion in renal transplant recipients. Cyclosporine 37-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 15367280-1 2004 The aim of this study was to study the incidence of chronic renal dysfunction in patients with more than 5 yr of follow-up following liver transplantation and to evaluate the benefit of decreasing cyclosporine A (CsA) dose combined with mycophenolate mofetil (MMF) on renal function and immune response in these patients. Cyclosporine 197-211 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 213-216 15599881-1 2004 Cyclosporine (CsA) has been the cornerstone of immunosuppression for organ transplantation since its introduction. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 15599881-5 2004 Moreover, the measurement of CsA at peak, around 2 hours after Neoral administration, proved to be a reliable index of the drug exposure, thus allowing efficient drug monitoring. Cyclosporine 63-69 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 29-32 15621114-2 2004 Blood levels of cyclosporine (CsA) necessary to avoid rejection may vary with different drug combinations. Cyclosporine 16-28 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 30-33 15184995-1 2004 PURPOSE: To determine the response rate to 26-h continuous infusion cyclosporine A (CSA) combined with a fixed dose level of carboplatin (CBDCA) in patients with recurrent ovarian cancer, and to determine the effect of CSA on the pharmacokinetics of CBDCA. Cyclosporine 68-82 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 84-87 15461875-3 2004 Cyclosporine (CsA) inhibits the proliferation and the IL-2 dependent expansion of T-lymphocytes. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 15518736-13 2004 Patients who received cyclosporine (CSA), prednisone (Pred), and mycophenolate mofetil (MMF) showed better graft survival than ones on CSA, Pred, and azathioprine (Aza) (P = .18). Cyclosporine 22-34 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 36-39 15353287-1 2004 Cyclophilin (CyP) is a cytosolic receptor of immunosuppressive drug cyclosporin A (CsA). Cyclosporine 68-81 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 83-86 15531003-2 2004 In the past decade, immunosuppressive drugs such as cyclosporine (CsA) and cyclophosphamide have been introduced for the treatment of SRNS, but data on long-term clinical outcome (over years) are lacking. Cyclosporine 52-64 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 15248059-1 2004 Clinical trials in adult liver and heart recipients have shown that management of cyclosporine (CsA) dose with 2-h levels (C2) leads to lower rejection rates and serum creatinine levels compared with C0 monitoring. Cyclosporine 82-94 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 96-99 15205865-1 2004 Cyclosporine (CsA) is a critical-dose drug for which a minor change in absorption can have important clinical implications. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 15242822-2 2004 Treatment of the cells with cyclosporine A (CsA) for 4h reduced glutamate-induced cell death by 60% (IC(50) of 7.1microM). Cyclosporine 28-42 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 44-47 15233825-3 2004 In this open randomized study, we compared the efficacy and safety of administration of cyclosporine (CSA; Neoral) and azathioprine before renal transplantation with the administration of the same schema after transplantation, in HLA haploidentical grafts. Cyclosporine 88-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 15205865-4 2004 The limited available clinical evidence has shown that stable renal transplant patients receiving Neoral have a significant reduction in mean CsA trough level after transfer to the Cicloral formulation. Cyclosporine 181-189 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 142-145 15108248-1 2004 Adjusting cyclosporine (CsA) dose based on blood concentration at 2 hours after dose (C(2)) has been shown in prospective clinical trials to reduce the risk of rejection compared with conventional trough monitoring. Cyclosporine 10-22 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 24-27 15192137-8 2004 The risk of graft loss was significantly higher for cyclosporine (CsA), prednisone (P) and azathioprine (Az) than for CsA + P, which in turn was higher than for CsA + P plus polyclonal antibodies [antilymphocyte globulin (ALG)/antithymocyte globulin (ATG)]. Cyclosporine 52-64 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 15370291-2 2004 To test the hypothesis that estradiol (E2) and cyclosporin A (CsA) can interfere within programmed cell death in human umbilical vein endothelial cells (HUVECs), apoptosis was induced by etoposide with and without E2 or CsA. Cyclosporine 47-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-65 15149317-1 2004 BACKGROUND: The clinical utility of cyclosporine A (CsA) has been limited by its nephrotoxicity, which is characterized by tubular atrophy, interstitial fibrosis, and progressive renal impairment. Cyclosporine 36-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 15108262-1 2004 It has been demonstrated that achieving therapeutic levels of cyclosporine (CsA) exposure in the first days posttransplant is critical for effective prevention of rejection. Cyclosporine 62-74 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 76-79 15016128-1 2004 BACKGROUND: Cyclosporine (CsA) 2-h post-dose levels (C(2)) correlate better with the area-under-the-curve compared with trough levels. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 15063039-1 2004 The cyclic endecapeptide cyclosporine (CsA), a potent immunosuppressive drug, was incorporated into biodegradable poly (DL-lactide-co-gylcolide) (DL-PLG) 50/50, 65/35 and PEG 5000-70/30 DL-PLG to improve the oral bioavailability and pharmacokinetics. Cyclosporine 25-37 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 39-42 14687467-1 2003 OBJECTIVE: To investigate retrospectively the efficacy of cyclosporine A (CsA) in the treatment of membranous lupus nephropathy (MLN). Cyclosporine 58-72 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 74-77 15084935-1 2004 BACKGROUND: Cyclosporine (CsA) is a substrate for the MDR-1 gene product P-glycoprotein (P-gp). Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 15515807-1 2004 Cyclosporine A (CsA) is one of the basic and often used immunosuppressive agents. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 15041327-1 2004 Six hundred thirty-eight cadaveric kidney transplant patients between 1983 and 2001 were treated with cyclosporine (CsA) for 87 +/- 58 months. Cyclosporine 102-114 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 116-119 15041336-1 2004 Cyclosporine A (CsA) was introduced to pediatric renal transplantation more than 20 years ago, and it has greatly improved graft survival and made transplantation the treatment of choice for children with end-stage renal failure. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 14625575-1 2003 We retrospectively analyzed the factors that affect serum cyclosporine (CsA) concentrations up to day 14 after allogeneic hematopoietic stem cell transplantation (HSCT). Cyclosporine 58-70 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 72-75 14697940-1 2003 Gastric emptying time (GET) appears to be a rate-limiting factor in the absorption of cyclosporine-A (CsA) and may be responsible for intra- and interpatient variability of CsA bioavailability. Cyclosporine 86-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 14659903-1 2003 Cyclosporin (CsA) or tacrolimus (TRL) is routinely combined with either sirolimus (SRL) or mycophenolate mofetil (MMF) in immunosuppressive regimes in organ transplantation. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 14697998-1 2003 Cyclosporine (CsA), a calcineurin inhibitor, has been associated with endothelial dysfunction in transplant patients. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 12829603-1 2003 Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be used to treat the cytopenia associated with myelodysplastic syndrome (MDS). Cyclosporine 55-67 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 69-72 14602422-5 2003 Cyclosporin A (CsA), a poorly water soluble immunosuppressant, was selected as model drug. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 12873538-1 2003 BACKGROUND: Cyclosporin (CsA) dose selection is complicated by significant pharmacokinetic variability between patients. Cyclosporine 12-23 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 25-28 12953048-2 2003 Trials of cyclosporine (CsA) treatment of nephrosis, the rationale of which was based on pathophysiologic considerations, have shown that this immunophillin modulator is effective in inducing and maintaining remission in patients suffering from idiopathic nephrotic syndrome. Cyclosporine 10-22 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 24-27 12860007-2 2003 Both cyclosporine-A (CSA) and liposome-encapsulated daunorubicin, DaunoXome (DNX) may reduce the negative impact of MDR. Cyclosporine 5-19 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 21-24 12860008-2 2003 A Phase II study of Mylotarg, fludarabine, ara-C and the MDR-modifier, cyclosporine (CSA) (MFAC) was conducted in 32 patients with primary resistant (11, 34%) or relapsed (21, 66%) AML. Cyclosporine 71-83 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 85-88 12877359-1 2003 Species differences in the interactions of cyclosporine A (CSA) and tacrolimus (TAC) with the cytochrome P450 (CYP) system in male rat and human liver were investigated in vitro by assessing effects on a series of model reactions for different CYP isoforms. Cyclosporine 43-57 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 59-62 12766570-1 2003 C(2) Cyclosporine (CsA) level, as a surrogate of area under the time-concentration curve (AUC) 0-4 hours, is a good predictor of drug absorption and clinical outcome after kidney transplantation. Cyclosporine 5-17 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 19-22 12570836-1 2003 Cyclosporin A (CSA) has transformed clinical transplantation, both in term of success and of quality-of-life of the patient. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 12654050-1 2003 Despite the introduction of a variety of new immunosuppressive agents, cyclosporine A (CsA) has maintained a strong position in pediatric transplantation (Tx). Cyclosporine 71-85 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 12709079-1 2003 Calcineurin inhibition with tacrolimus has been used after renal transplantation (RTPL) as rescue therapy for insufficient immunological control or if cyclosporin A (CSA) toxicity occurred. Cyclosporine 151-164 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 166-169 12838495-5 2003 We present the data from studies of cyclosporine (CSA) and mycophenolate mofetil (MMF) treatment of IMN with their level of evidence in support of efficacy. Cyclosporine 36-48 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 50-53 12646197-1 2003 Tacrolimus (Tac) is more immunosuppressive drug compared to cyclosporine (CsA). Cyclosporine 60-72 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 74-77 12410861-8 2002 Also, in renal transplant patients initially immunosuppressed with rapamycin, cyclosporine and corticosteroids, after the elimination of CSA, a lower blood pressure is achieved. Cyclosporine 78-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 137-140 12499901-1 2002 BACKGROUND: Population data indicate that cyclosporine (CsA)-based immunosuppression has had relatively little effect on late renal allograft loss. Cyclosporine 42-54 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 56-59 12592084-2 2003 While systemic cyclosporin (CsA) represents a well-established therapy of psoriasis, its topical use is limited by the difficult penetration of the molecule through the skin and the nail because of its highly lipophilic nature. Cyclosporine 15-26 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 28-31 12377217-1 2002 Cyclosporin A (CsA) specifically inhibits mammalian T cells by preventing activation of transcription factors (termed nuclear factor of activated T cells (NFAT)) involved in cytokine gene expression. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 12469783-1 2002 I present a review of the current US Food and Drug Administration (FDA) guidelines for using cyclosporine A (CSA) to treat psoriasis, with particular emphasis on the period for which CSA may be administered. Cyclosporine 93-107 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 109-112 12445178-6 2002 The administration of prednisolone (PSL) and cyclosporin (CsA) ameliorated laboratory data to a degree, but they did not return to normal. Cyclosporine 45-56 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 58-61 12207006-2 2002 Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 12207006-2 2002 Data regarding the role of cyclosporine (CsA) and FK-506 in AMT have shown that CsA is less effective than FK-506. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 80-83 12376808-5 2002 In the cyclosporine (CsA) era, survival of grafts from living related (LRD) and cadaver (CD) donors in Stx-HUS and control patients was 83% versus 70% ( P<0.03) and 77% versus 49% ( P<0.05) at 10 years. Cyclosporine 7-19 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 21-24 12395977-1 2002 OBJECTIVE: The aim of the present study was to investigate the effect of grapefruit juice on the pharmacokinetics of cyclosporin A (CsA), as Sandimmun Neoral, and its main metabolites, M1, M9 and M4N, in renal transplant recipients. Cyclosporine 117-130 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 132-135 11961080-1 2002 By virtue of its binding to cyclophilin, the cellular receptor for cyclosporine (CsA), we could identify a new compound D-43787 [N-[(1-tert-butyloxycarbonyl)-indolin-2-(S)-carbonyl]-indolin-2-(S)-carbonacid-[N-epsilon-benzyloxycarbonyl)-2-(S)-lysin methylester]-amide] exhibiting immunomodulating properties. Cyclosporine 67-79 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 12181023-1 2002 Recent studies have shown a good response to immunosuppressive treatment with cyclosporin A (CSA) in patients with the myelodysplastic syndrome (MDS). Cyclosporine 78-91 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 93-96 12102473-2 2002 OBJECTIVE: To evaluate the ability of two different combination therapies with prednisone (PDN), methotrexate (MTX) and cyclosporine (CSA) to modulate both TNFalpha transcription and production in early rheumatoid arthritis (RA). Cyclosporine 120-132 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 134-137 11956176-1 2002 Renal transplant recipients treated with cyclosporine A (CsA) and FK506 (tacrolimus) develop signs of hypoaldosteronism despite normal plasma aldosterone levels, suggesting a relative resistance of the distal nephron to aldosterone action. Cyclosporine 41-55 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 57-60 11922262-3 2002 The role of cylosporin A (CsA) in aggravating bone loss is controversial. Cyclosporine 26-29 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 12-24 11893438-2 2002 AIM: To investigate the influence of ciclosporine A (CsA) on the vasoactive effects of serotonin in human umbilical arteries. Cyclosporine 53-56 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-51 11868803-1 2002 OBJECTIVES: Area under the curve (AUC)-based monitoring of cyclosporin (CsA) could help to optimise therapeutic drug monitoring in certain transplant patients in addition to trough concentration monitoring. Cyclosporine 59-70 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 72-75 11700317-1 2002 Cyclosporin A (CsA) treatment of HEK 293 cells expressing the rat heart RHE-1 (NCX1.1, EMBL accession number ) or the rat brain RBE-2 (NCX1.5, GenBank(TM) accession number ) Na(+)-Ca(2+) exchanger inhibited their transport activity in a concentration-dependent manner. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 11758550-0 2001 Comments on experimental use of intravenous cyclosporine (CsA) alone to treat severe ulcerative colitis. Cyclosporine 44-56 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 58-61 11781620-2 2001 He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Cyclosporine 70-81 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 83-86 11493443-2 2001 The MDR phenotype often correlates with expression of P-glycoprotein (Pgp), and Pgp antagonists such as cyclosporine (CSA) have been used as chemosensitizing agents in AML. Cyclosporine 104-116 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 118-121 11701197-2 2001 The present study was aimed at elucidating the pharmacological characterization of cyclosporine A (CsA)-induced kaolin intake in rats. Cyclosporine 83-97 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 99-102 11770808-4 2001 Cyclosporine (CsA), a fungal decapeptide first introduced in 1983, has significantly improved the outcome of renal transplantation, and remains the first line immunosupressant for pediatric recipients. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 11605779-1 2001 Like cyclosporine (CsA), tacrolimus acts through the inhibition of renal phosphatase calcineurin. Cyclosporine 5-17 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 19-22 11683823-1 2001 To determine whether conversion from cyclosporin A (CsA) to tacrolimus (TAC)-based immunosuppressive therapy is safe and might lead to improvement in the clinical side effect profile we studied 55 cardiac allograft recipients. Cyclosporine 37-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 11436960-1 2001 A 10-year-old boy with a history of heart transplantation had a potentially life-threatening decrease in his cyclosporine (CSA) blood levels during administration of bupropion. Cyclosporine 109-121 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 123-126 11722596-1 2001 OBJECTIVES: Severe neurotoxicity is a recognized complication of cyclosporin A (cyclosporine, CSA). Cyclosporine 65-78 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 11399919-1 2001 BACKGROUND/AIM: In idiopathic nephrotic syndrome (INS), ciclosporin A (CsA) was shown to decrease proteinuria, an effect explained by its immunologic and hemodynamic actions. Cyclosporine 71-74 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 56-69 11323421-3 2001 In the present work, we demonstrate that the immunosuppressant cyclosporin A (CSA) reduces the frequency of IP(3)-dependent [Ca(2+)](i) oscillations in intact hepatocytes, apparently by altering the local Ca(2+) gradients. Cyclosporine 63-76 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 78-81 11274282-2 2001 The primary aim of the present prospective observational study was to test the hypothesis that tapering off prednisolone and cyclosporin (CsA) the first year after transplantation may have beneficial effects on glucose tolerance in renal transplant recipients. Cyclosporine 125-136 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 138-141 11193184-1 2001 The immunosuppressant drug cyclosporin A (CsA) is known to cause reduction in number, DNA synthesis and function of Langerhans cells (LC). Cyclosporine 27-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 11278005-1 2001 Cyclosporin A (CsA) is a widely used immunosuppressive agent with severe side effects including hypertension. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 11261685-6 2001 We conclude that Neoral results in an increased bioavailability of cyclosporine (CsA) as compared to Sandimmun in patients with steroid-dependent nephrotic syndrome in remission. Cyclosporine 67-79 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 11549851-1 2001 BACKGROUND: Hyperkalemia and metabolic acidosis are common manifestations in patients receiving the immunosuppressive agent cyclosporine A (CsA) and the recently introduced FK506. Cyclosporine 124-138 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 140-143 11228175-1 2001 In a prospective randomized study including 100 kidney transplant recipients, we previously reported on the safety and financial benefits of the coadministration of ketoconazole (keto) to cyclosporine (CsA)-treated kidney transplant recipients. Cyclosporine 188-200 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 202-205 11136176-1 2001 High treatment costs force the discontinuation of cyclosporine (CSA) in a vast majority of renal transplant recipients in India. Cyclosporine 50-62 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 64-67 11769390-1 2001 Multiple clinical trials have been undertaken during last years to assess indications, efficiency and safety of glomerulonephritis treatment with new immunosuppressive drugs as cyclosporine (CsA, Mycophenolate Mophetil (MMF) and Tacrolimus (FK 506). Cyclosporine 177-189 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 191-194 10878286-1 2000 Cyclosporine (cyclosporin A, CsA) has potent immunosuppressive properties, reflecting its ability to block the transcription of cytokine genes in activated T cells. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 29-32 11117367-1 2000 Chronic treatment with Sandimmune (cyclosporine A [CsA] dissolved in Cremophor EL [CrEL]) is often associated with hypertension and nephrotoxicity. Cyclosporine 35-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 11048998-4 2000 IL-2 receptor antibodies have been shown to decrease rejection rates when added to a regimen of cyclosporine (CsA), azathioprine and prednisone. Cyclosporine 96-108 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 110-113 11019845-1 2000 Cyclosporin A (CsA) absorption is highly variable in BMT patients. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 11124491-1 2000 BACKGROUND: Management of cyclosporine (CsA)-associated hyperuricemia in heart transplantation (HT) is difficult. Cyclosporine 26-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 40-43 10964494-1 2000 Cyclosporin A (CsA) has been shown to be efficacious in protecting against ischemic injury after short periods (5 to 10 min) of forebrain ischemia. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 10836367-1 2000 BACKGROUND: Cyclosporine (CsA) nephrotoxicity is a common problem after cardiac transplantation. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 10775814-1 2000 OBJECTIVES: This study analyzed the relationship of variability in routine trough cyclosporine (CSA) levels to morbidity after pediatric cardiac transplantation. Cyclosporine 82-94 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 96-99 10775814-8 2000 Cyclosporine variability was measured as the percentage of CSA levels that were considered sub-therapeutic (< or = 100 ng/ml), toxic (> or = 450 ng/ml), or both. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 59-62 10714397-1 2000 PURPOSE: Cyclosporine (CSA) toxicity represents a common cause of seizures in transplant patients, but the specific mechanisms by which CSA induces seizures are unknown. Cyclosporine 9-21 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 23-26 10774626-1 2000 The range of cyclosporin (CsA) immunoassays has become the mainstay in many therapeutic drug monitoring laboratories for delivering CsA concentration data to support clinical care of patients after transplantation. Cyclosporine 13-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 10774626-1 2000 The range of cyclosporin (CsA) immunoassays has become the mainstay in many therapeutic drug monitoring laboratories for delivering CsA concentration data to support clinical care of patients after transplantation. Cyclosporine 13-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 132-135 10897619-1 2000 MDR1 gene encodes for a transmembranous glycoprotein, gp-170, which acts as a drug export pump and is also a cyclosporine(CsA)-binding protein. Cyclosporine 109-121 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 122-125 10676915-5 2000 While combined immunosuppression with both antithymocyte globulin (ATG) and cyclosporine A (CSA) produces hematologic improvement in most patients, relapse is common. Cyclosporine 76-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 12579726-1 2000 OBJECTIVE: To observe the effects of immunosuppressants triptolide (TL) and cyclosporine A (CSA) on HLA antigens expression induced by interferon-gamma(INF-gamma) in vitro. Cyclosporine 76-90 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 92-95 11347860-1 2000 Cyclosporine (CsA) treatment in solid organ transplantation has represented one of the greatest advances in the past 20 years, reducing acute rejection and increasing long-term survival. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 10580348-3 1999 We have previously demonstrated that cyclosporine (CsA) in conjunction with rapamycin (RAPA) potentiates class I+, class II- donor-specific hepatocytes to prolong rat cardiac and small bowel allograft survival. Cyclosporine 37-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 11112023-1 2000 Cyclosporine (CsA) reduces nitric oxide (NO) production in medullary thick ascending limb (mTAL) cells. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 11112045-1 2000 Hypertension is a major side effect of cyclosporin (CsA). Cyclosporine 39-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 10573076-1 1999 BACKGROUND: Cyclosporine (CsA) acts by inhibiting the phosphatase calcineurin (CN), but the time course and extent of inhibition in vivo are unknown. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 10432409-5 1999 The cyclosporine (CsA) dose was adjusted as necessary to maintain site-specific trough whole blood levels. Cyclosporine 4-16 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 18-21 10471650-1 1999 BACKGROUND: Prediction of cyclosporine (CSA) efficacy and toxicity in individual patients is difficult. Cyclosporine 26-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 40-43 10492062-1 1999 BACKGROUND: A large number of drugs have been shown to affect the metabolism of cyclosporin A (CSA) and, since cyclosporin is characterized by a narrow therapeutic range, the consequences of such drug interactions may often be of clinical importance. Cyclosporine 80-93 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 95-98 10492062-1 1999 BACKGROUND: A large number of drugs have been shown to affect the metabolism of cyclosporin A (CSA) and, since cyclosporin is characterized by a narrow therapeutic range, the consequences of such drug interactions may often be of clinical importance. Cyclosporine 80-91 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 95-98 10364029-1 1999 OBJECTIVE: Cyclosporin (CSA) is a promising alternative for patients with severe steroid-refractory ulcerative colitis (UC) previously facing only surgical options. Cyclosporine 11-22 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 24-27 10465413-1 1999 Cyclosporin A (CsA) and FK506 are potent natural product immunosuppressants that induce their biological effects by forming an initial complex with cytosolic proteins termed immunophilins. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 10386979-1 1999 Cyclophilin B (CyPB) is a cyclosporin A (CsA)-binding protein mainly located in intracellular vesicles and secreted in biological fluids. Cyclosporine 26-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 10202617-2 1999 The introduction of a microemulsion preparation, CsA-ME (Neoral), with less variable pharmacokinetics, has made it possible to attempt to define its use more closely. Cyclosporine 57-63 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 10399863-1 1999 Cyclosporin A (CsA) induces neurological side effects in up to 40% of patients. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 9850449-2 1998 However, a published case report has indicated a possible interaction of glipizide with cyclosporine (CsA) pharmacokinetics in two renal transplant (tx) patients. Cyclosporine 88-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 10078836-2 1999 Cyclosporin A (cyclosporine, CSA) is an immunosuppressive drug with a narrow therapeutic index. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 29-32 10500807-4 1999 The apoptotic effect from varying drug type and concentration was compared at 24 hours in CEM-MDR1+ cells, with and without co-incubation with MDR1 functional downregulator cyclosporin A (CSA) used at therapeutic concentration (1500 ng/ml). Cyclosporine 173-186 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 188-191 10989666-2 1999 The discovery that cyclosporin A (CsA) inhibits the pore proved instrumental. Cyclosporine 19-32 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 34-37 10755366-1 1999 Toxicity of cyclosporine (CsA), an immunosuppressive drug widely used in transplantation, to the transplanted kidney creates a serious side effect. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 9709036-1 1998 The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506. Cyclosporine 38-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 9825816-1 1998 BACKGROUND: Since the introduction of cyclosporine (CsA), 1-year renal allograft survival has improved, but concern persists about the long-term adverse effects of CsA, especially with respect to renal function and blood pressure. Cyclosporine 38-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 9794567-1 1998 BACKGROUND: In renal transplantation the beneficial immunosuppressive effects of cyclosporin (CsA) may be curtailed by its nephrotoxicity, specially in patients receiving a cadaveric allograft from suboptimal donors or at risk of delayed graft function. Cyclosporine 81-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 9794569-1 1998 BACKGROUND: Immunosuppressive treatment with cyclosporin A (CsA) improves the survival of renal allografts, but is associated with renal vasoconstriction and hypertension. Cyclosporine 45-58 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 60-63 9709036-1 1998 The immunosuppressive fungal products cyclosporin A (CsA) and FK506 bind with high affinity to intracellular receptor proteins: cyclophilin (CYP) is one of the receptors for CsA and FK506-binding protein (FKBP) is one of the receptors for FK506. Cyclosporine 38-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 174-177 9565092-1 1998 BACKGROUND: We examined the ability of FTY720, a novel immunosuppressant that prolongs the survival of allografts in experimental animal models, to potentiate the immunosuppressive effects of cyclosporine (CsA) and/or sirolimus (SRL) in vitro and in vivo. Cyclosporine 192-204 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 206-209 9746235-1 1998 Frequent monitoring of immunosuppressive drug cyclosporine A (CsA) in blood samples of tissue transplant patients is required in clinical practice because of the narrow therapeutic range between the immunosuppressive effect and the toxic effect of this drug. Cyclosporine 46-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-65 9706856-1 1998 Cyclosporine A(CsA) is successfully used to prevent graft rejection in organ transplantation and in the treatment of various systemic diseases. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 9558395-3 1998 We report reversal of severe neutropenia associated with T-LGL leukemia in five patients treated with cyclosporine (CSA). Cyclosporine 102-114 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 116-119 9758340-2 1998 For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Cyclosporine 91-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 9625027-3 1998 Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Cyclosporine 134-146 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 148-151 9582553-3 1998 A recent study suggested that cyclosporine (CsA) increased plasma homocyst(e)ine concentration in interfering with folate-assisted remethylation of homocysteine. Cyclosporine 30-42 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 44-47 9749227-1 1998 Cyclosporine (CsA) is an immunosuppressor widely used in all postoperative transplantation protocols. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 9583869-1 1998 BACKGROUND: Cyclophilin B (CyPB) is a cyclosporine (CsA)-binding protein, located within intracellular vesicles and secreted in biological fluids. Cyclosporine 38-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 9442391-1 1997 The isolation of Cyclosporin A (CsA) from cultures of the fungus Tolypocladium inflatum and its subsequent elucidation of immunosuppressive properties by Borel et al. Cyclosporine 17-30 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 32-35 9545147-1 1998 STUDY OBJECTIVE: To evaluate the utility of cyclosporine (CsA) trough concentrations as a monitoring tool for acute graft rejections and CsA nephrotoxicity. Cyclosporine 44-56 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 58-61 9545156-1 1998 We attempted to characterize circadian variations in pharmacokinetic parameters of a new formulation of cyclosporine (CsA) in nine cardiac allograft recipients. Cyclosporine 104-116 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 118-121 9458024-1 1998 BACKGROUND: Mothers treated with cyclosporine (CsA) have previously not been allowed to breast-feed due to the reported accumulation of the drug in breast milk. Cyclosporine 33-45 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 47-50 9448137-1 1998 BACKGROUND: Tacrolimus (FK506) is an immunosuppressive drug 50-100 times more potent than cyclosporine (CsA), the current mainstay of organ transplant rejection therapy. Cyclosporine 90-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 9422406-3 1997 METHODS: Twenty-eight cyclosporine (CsA)-treated renal transplant recipients (21 cadaveric, 5 living, 2 simultaneous kidney-pancreas) with progressive deterioration of renal function were prospectively enrolled in a clinical trial and had their immunosuppressive regimen changed 24.3+/-7.7 months after transplant. Cyclosporine 22-34 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 36-39 9846420-4 1998 Patients were induced with intravenous cyclosporine (CsA) then switched to Neoral or Sandimmune. Cyclosporine 39-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 9408683-2 1997 We previously noted that low cyclosporine (CsA) levels were a risk factor for early acute rejection in pediatric recipients (1). Cyclosporine 29-41 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 43-46 9370178-1 1997 Calcium antagonists may reduce the nephrotoxicity of cyclosporine (CsA), allowing CsA to be introduced immediately after renal transplantation and thereby obviating the need for sequential induction therapy with a monoclonal or polyclonal antibody. Cyclosporine 53-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 67-70 9370178-1 1997 Calcium antagonists may reduce the nephrotoxicity of cyclosporine (CsA), allowing CsA to be introduced immediately after renal transplantation and thereby obviating the need for sequential induction therapy with a monoclonal or polyclonal antibody. Cyclosporine 53-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 82-85 9245491-1 1997 Previous studies have shown interindividual heterogeneity in the suppressive effects of glucocorticoids and cyclosporine (CsA) on the proliferation responses of dialysis patients" peripheral blood mononuclear cells (PBMC). Cyclosporine 108-120 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 122-125 9438176-1 1997 We investigated the influence of cyclosporine A (CsA) on key plasma membrane ion transport systems Na+/K(+)-ATPase, Na+/K+/2Cl- cotransporter, and H+/K(+)-ATPase in MDCK cells and two subtypes, C7 and C11, serving as a model system to study principal (C7) and intercalated (C11) cell properties of the distal nephron. Cyclosporine 33-47 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 9336420-2 1997 OBJECTIVE: To determine whether the clinical benefit and favorable safety profile previously noted with the combination of cyclosporine (CSA) and methotrexate (MTX) given for 24 weeks in patients with rheumatoid arthritis (RA) would be maintained for a further 24 weeks, and whether the addition of CSA in patients who had previously been randomized to receive placebo + MTX would result in clinical benefit. Cyclosporine 123-135 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 137-140 9409194-1 1997 Twenty-nine children with nephrotic syndrome were treated with cyclosporine (CsA), 100 mg/m2/day for 6 months and prednisone, 2 mg/kg every other day for 1 month and then subsequently 1 mg/kg every other day for 5 months. Cyclosporine 63-75 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 77-80 9396174-2 1997 Cyclosporin (CsA) has been proposed in the management of patients with acute ulcerative colitis (UC) in whom standard therapy failed and who were candidates for colectomy. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 9180163-1 1997 Cyclosporin A (CSA) is an effective inhibitor of the P-glycoprotein (P-gp) activity and has been shown to modulate multidrug resistance (MDR) in in vitro experimental models. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 9210502-1 1997 BACKGROUND: One-to-one (mg:mg) conversion from the conventional to the microemulsion formulation of cyclosporine (CsA) is advocated as a simple way to use the new therapeutic regimen. Cyclosporine 100-112 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 114-117 9193837-3 1997 In addition, PTX decreases cyclosporine (CsA) induced renal endothelial release and vasoconstriction. Cyclosporine 27-39 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 9234374-0 1997 Prevention of high risk corneal graft rejection using cyclosporine A (CsA) incorporated into a collagen matrix. Cyclosporine 54-68 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 70-73 9234374-1 1997 The aim of this work was to compare the efficacy of cyclosporine (CsA) collagen shields and fragments in suppressing experimental allograft rejection in an animal model for high risk keratoplasty. Cyclosporine 52-64 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 9158111-3 1997 The second model was one that required a 7-day (10 mg/kg) treatment with cyclosporin A (CsA) to achieve tolerance and used DA donors into Lewis (RT1(1)) recipients. Cyclosporine 73-86 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 88-91 9116920-1 1997 OBJECTIVES: Essential hypertension and insulin resistance frequently coexist; cyclosporine A (CsA) is known to induce hypertension which has been used as a model for essential hypertension. Cyclosporine 78-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 10495795-1 1997 Accurate monitoring of cyclosporine (CsA) dosage is still a problem, because measurement of the area under the curve (AUC)--the most appropriate indicator of exposure to CsA--requires a number of blood samples to be taken over 12 h, which makes monitoring difficult in day-to-day clinical practice. Cyclosporine 23-35 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-40 9075853-8 1997 The mean (+/- SD) CsA trough levels at end point were 187 +/- 63 and 210 +/- 95 ng/ml for CsA- and CsA-ME-treated patients, respectively. Cyclosporine 18-21 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 90-94 9075128-1 1997 BACKGROUND: Deterioration of renal function and rise in blood pressure are clinically important side-effects of cyclosporin (CsA) treatment. Cyclosporine 112-123 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 125-128 9067693-1 1997 Numerous drugs have been reported to alter cyclosporine (CSA) blood levels, most notably, those drugs that interfere with cytochrome P450 metabolism. Cyclosporine 43-55 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 57-60 9020336-2 1997 The combination of a single dose of rapamycin (RAPA) with a short course of cyclosporine (CsA) has been shown to induce transplantation tolerance in the nonfunctional rat heterotopic cardiac transplant model. Cyclosporine 76-88 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 90-93 9008597-1 1997 OBJECTIVE: To evaluate the efficacy of long-term treatment with cyclosporin A (CSA) in systemic lupus erythematosus (SLE). Cyclosporine 64-77 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 79-82 9126869-1 1997 Cyclosporine A (CsA) is a widely used immunosuppressant which possesses significant side effects including nephrotoxicity and systemic arterial hypertension. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 8990230-1 1997 The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation. Cyclosporine 28-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 8990230-1 1997 The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation. Cyclosporine 28-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 56-59 8990230-1 1997 The new oral formulation of cyclosporine (CsA), Neoral (CsA-N), results in increased area under the curve (AUC) and decreased intra- and interindividual variation in blood concentrations and other pharmacokinetic (PK) parameters when compared with the current Sand-immune (CsA-S) formulation. Cyclosporine 28-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 56-59 8996767-1 1996 We studied the impact of early cyclosporine (CSA) levels on the incidence of rejection in pediatric transplant recipients. Cyclosporine 31-43 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 45-48 8970613-1 1996 Transplant immunosuppression using either cyclosporine (CsA) or tacrolimus (FK506) leads to renal vasoconstriction and nephrotoxicity. Cyclosporine 42-54 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 56-59 8947290-1 1996 INTRODUCTION: Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Cyclosporine 49-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 63-66 8900321-1 1996 Hyperkalemia is the most frequent electrolyte abnormality found in whole organ transplant recipients receiving either cyclosporine (CsA) or tacrolimus (FK506). Cyclosporine 118-130 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 132-135 8931845-1 1996 The immunosuppressant drug cyclosporine A (CsA) has emerged as an important new cause of hypertension in both organ transplant recipients and patients with autoimmune diseases. Cyclosporine 27-41 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 43-46 8980883-2 1996 Having previously demonstrated differential suppressive effects of methylprednisolone (MP), prednisolone (P) and cyclosporine (CsA) on dialysis patients" lymphocyte proliferative responses to phytohaemagglutinin (PHA), we studied the effects of these drugs on dialysis patients" lymphocyte IFN-gamma production during mitogenic and allogeneic (MLR) stimulation. Cyclosporine 113-125 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 127-130 8840947-1 1996 Cyclosporine-associated thrombotic microangiopathy (CsA-TMA) is characterized by anemia, acute renal failure, and renal TMA. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 8738760-1 1996 The commonly used immunosuppressive regimen after orthotopic heart transplantation consists of cyclosporine (CsA), azathioprine (AZA), and steroids. Cyclosporine 95-107 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 109-112 8930454-9 1996 The absolute cyclosporine (CsA) requirement (mg/d) increased by approximately 33% (p = NS), and there was also a significant increase in the weight adjusted CsA requirement from 1.8 to 3.5 mg/kg/d (p = 0.02, ANOVA) following GBP in order to maintain similar TDX trough CsA levels. Cyclosporine 13-25 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 27-30 8781610-1 1996 Cyclosporine (CsA) is an immunosuppressive drug requiring dose individualization and regular control due to its highly variable pharmacokinetics. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 8781623-8 1996 Antilymphocyte induction therapy type had no influence, but the amount of immunosuppression with prednisone and cyclosporine (CsA) at 3 months posttransplant was significantly lower in those patients who experienced late rejection. Cyclosporine 112-124 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 126-129 8766550-1 1996 Cyclosporin A (CSA), an immunosuppressive agent used in organ transplantation and to treat some autoimmune diseases, blocks the Ca2+-dependent steps involved in T cell receptor triggering leading to interleukin (IL)-2 production. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 8665934-2 1996 The pore is blocked by cyclosporin A (CSA). Cyclosporine 23-36 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 38-41 8633383-1 1996 In vitro studies have shown that the immunosuppressive property of cyclosporine (CsA) depends on its ability to inhibit the phosphatase activity of calcineurin, a critical enzyme for T cell activation. Cyclosporine 67-79 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 81-84 8724887-1 1996 Cyclosporine (CsA) is effective in treating steroid-dependent (SDNS) and steroid-resistant (SRNS) nephrotic syndrome (NS) in children, but because of the potential for chronic nephrotoxicity, its long-term use is controversial. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 8621208-1 1996 Increasing evidence suggests that endothelin, a potent vasoconstrictor, is implicated in cyclosporin A (CsA)-induced nephrotoxicity. Cyclosporine 89-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 8601324-1 1996 OBJECTIVES: We wish to examine the role of lipoproteins in the transport and cellular uptake of cyclosporine (CsA) and tacrolimus. Cyclosporine 96-108 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 110-113 8613950-1 1996 When applied to rat liver mitochondria in contact with Ca++, cyclosporine A (CsA) induced both an accumulation of this ion and a decrease in oxidative phosphorylation. Cyclosporine 61-75 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 77-80 8785399-1 1996 Forty-one patients with a nephrotic syndrome and biopsy-proven membranous nephropathy were administered a 3 to 6-month course of cyclosporine (CsA;4 to 5 mg/kg per day). Cyclosporine 129-141 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 143-146 8708940-1 1996 Cyclosporine (CsA) is a selective immunosuppressant widely used in clinical therapy. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 8808110-4 1996 In addition to the work presented in this study, there have been many reports of the potential effectiveness of cyclosporine (CSA) on reducing the proteinuria of FSGS. Cyclosporine 112-124 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 126-129 8545866-8 1995 (5) Cyclosporine (CsA) toxicity was implicated in only 3 recipients, who had mild diffuse interstitial fibrosis in association with elevated CsA levels. Cyclosporine 4-16 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 18-21 9172006-1 1996 In the present work, we have studied the prediction of blood cyclosporine (CsA) concentrations in haematological patients with multidrug resistance by means of total body weight, 25, 50 and 75 adipose factor dosing body weight, and lean body weight using the Bayesian method (BM) and non-linear least squares method (NLLSM) during the second course of CsA treatment. Cyclosporine 61-73 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 75-78 8545869-8 1995 Cumulative prednisone dose (mg/kg) as well as cyclosporine (CsA) dose (mg/kg) at one year was not significantly different between obese and nonobese patients. Cyclosporine 46-58 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 60-63 8610498-1 1995 INTRODUCTION: Cortical blindness, a rare form of cyclosporine (CSA) neurotoxicity, has previously been described in only nine bone marrow transplant (BMT) recipients. Cyclosporine 49-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 63-66 8605709-2 1995 Fifteen renal transplant hypertensive and proteinuric patients on triple drug treatment with cyclosporin (CSA), azathioprine and methylprednisolone entered the therapeutic protocol of this study. Cyclosporine 93-104 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 106-109 7595701-1 1995 PURPOSE: An unusually high incidence of anaphylactoid reactions was observed during a phase I/II trial of high-dose intravenous cyclosporine (CsA) therapy to attenuate tumor multidrug resistance (MDR). Cyclosporine 128-140 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 142-145 7673124-1 1995 In complex with the peptidyl-prolyl isomerase cyclophilin A, the immunosuppressive antifungal drug cyclosporin A (CsA) inhibits a Ca2+/calmodulin-dependent protein phosphatase, calcineurin, which regulates signal transduction. Cyclosporine 99-112 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 114-117 19077999-3 1995 Visceral involvement, particularly pulmonary interstitial disease, can lead to significant morbidity and mortality.Specific therapy is unavailable to date, but there has been interest in the use of cyclosporine (CSA), because it inhibits interleukin-2 production and affects cytotoxic T cells. Cyclosporine 198-210 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 212-215 11850697-1 1995 The effect of a standard regimen of the investigational macrolide antibiotic, dirithromycin, on the single-dose kinetics of orally administered cyclosporine (CSA) was investigated in healthy young males and on the steady-state disposition kinetics of cyclosporine in a panel of renal transplant patients. Cyclosporine 144-156 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 158-161 7666081-1 1995 PURPOSE: To determine the maximal-tolerated dose (MTD) of infusional cyclosporine (CSA) with fixed-dose carboplatin (CBDCA). Cyclosporine 69-81 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 83-86 7544983-1 1995 Hypertension, which develops after organ transplantation during immunosuppression with cyclosporine (CSA), is often associated with a loss of nocturnal decrease in blood pressure. Cyclosporine 87-99 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 101-104 11850697-15 1995 The magnitude of the pharmacokinetic changes for CSA during dirithromycin treatment (<15% in normal subjects and 15--20% in renal transplant patients) when considered in the context of the therapeutic range of cyclosporine concentrations was relatively small, and not likely to warrant special attention to the dosing of CSA in such patients beyond routine whole-blood CSA and serum creatinine monitoring. Cyclosporine 213-225 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 7752996-2 1995 Preliminary reports suggest some effect of cyclosporine (CSA), both alone or in combination with steroids and/or vinblastine, in untreated cases. Cyclosporine 43-55 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 57-60 7601144-2 1995 Pore opening is blocked by cyclosporin A (CSA). Cyclosporine 27-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 7549062-5 1995 Increased doses of systemically administered cyclosporin-A (CSA) were necessary to maintain therapeutic levels for 2 patients. Cyclosporine 45-58 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 60-63 7794760-1 1995 Cyclosporin A (CSA) exhibits greater multidrug resistance (MDR) modulating activity in vitro than other MDR modulators such as verapamil and quinidine. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 7770925-2 1995 In lymphocytes in vitro, cyclosporine (CsA) blocks the phosphatase activity of the enzyme calcineurin, preventing cytokine induction. Cyclosporine 25-37 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 39-42 7774069-1 1995 Our studies on the treatment of psoriasis with cyclosporine A (CSA) have demonstrated efficacy at doses < 5 mg/kg/day. Cyclosporine 47-61 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 63-66 7667170-1 1995 This study documents a pharmacokinetic interaction between carbamazepine and cyclosporine (CsA) in pediatric renal transplant recipients. Cyclosporine 77-89 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 91-94 7878758-1 1995 We tested the hypothesis that there would be a difference in the unwanted side effects of cyclosporine (CsA) when heart transplant patients received CsA once a day versus half the dose twice a day. Cyclosporine 90-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 7842214-1 1995 The aim of the present study was to identify factors determining the delivery to and distribution of aerosolized cyclosporine A (CSA) in the lungs of patients with severe pulmonary allograft rejection. Cyclosporine 113-127 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 129-132 7478116-1 1995 Cyclosporin A (CsA) can reduce proteinuria in various forms of human and experimental glomerulonephritis. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 8093097-0 1994 Evidence that inhibition of phorbol ester-induced superoxide anion formation by cyclosporin A in phagocytes is not mediated by direct inhibition of protein kinase C. Cyclosporin A (CsA) has been reported to inhibit phorbol myristate acetate (PMA)-induced superoxide anion (O2-) formation in human neutrophils and murine macrophages. Cyclosporine 80-93 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 181-184 7980456-1 1994 Cyclophilin A, the major intracellular binding protein for the immunosuppressive drug cyclosporin A (CsA), was studied in human keratinocytes during differentiation both in vivo and in vitro. Cyclosporine 86-99 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 101-104 7899577-1 1994 Cyclosporin A (CsA)-induced nephrotoxicity is characterized by a decrease in the glomerular filtration rate (GFR) which is associated with a large increase in renal vascular resistance (RVR). Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 7527575-1 1994 The nephrotoxicity of cyclosporin A (CSA) after chronic treatment is well known and includes in later stages tubular atrophy associated with interstitial fibrosis. Cyclosporine 22-35 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 37-40 8093097-0 1994 Evidence that inhibition of phorbol ester-induced superoxide anion formation by cyclosporin A in phagocytes is not mediated by direct inhibition of protein kinase C. Cyclosporin A (CsA) has been reported to inhibit phorbol myristate acetate (PMA)-induced superoxide anion (O2-) formation in human neutrophils and murine macrophages. Cyclosporine 166-179 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 181-184 8009178-1 1994 Cyclosporin (CsA) is a potent immunosuppressive drug widely used in organ transplantation. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 8075536-1 1994 The three-dimensional NMR solution structure of the cyclophilin A (Cyp)-cyclosporin A (CsA) complex was determined, and here we provide a detailed description of the analysis of the NMR data and the structure calculation. Cyclosporine 72-85 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 9527588-5 1997 Only the use of systemic cyclosporin A (CSA) treatment appears for the first time to have a significant positive effect on the outcome. Cyclosporine 25-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 40-43 8185690-1 1994 OBJECTIVE: To investigate whether low-dose cyclosporin A (CSA) is safe and effective in comparison with chloroquine (CQ) in patients with early rheumatoid arthritis (RA). Cyclosporine 43-56 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 58-61 8190466-3 1994 Steroid-sparing strategies with more specific agents such as cyclosporine (Cyclosporin A, CSA) have been suggested as the first line treatment for this disease. Cyclosporine 61-73 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 90-93 8151326-1 1994 PURPOSE: To study the effects of cyclosporine (CsA), a modulator of multidrug resistance (MDR), on the pharmacokinetics and toxicities of doxorubicin. Cyclosporine 33-45 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 47-50 8129618-1 1994 The effect of the immune modulator, Cyclosporin A (CsA) on vaccinia virus replication has been examined in cell cultures. Cyclosporine 36-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 8075981-1 1994 BACKGROUND: Cyclophilin (CyP) is a ubiquitious intracellular protein that binds the immunosuppressive drug cyclosporin A (CsA). Cyclosporine 107-120 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 122-125 7511575-1 1994 Cyclosporin A (CsA) was previously found to bind to P-glycoprotein expressed on multidrug-resistant (MDR) cancer cells. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 8302545-4 1994 Cyclosporine (CSA) given systemically prevents graft rejection, but because of the potential side effects and cost, the duration of treatment is an important factor. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 7988626-1 1994 The pharmacokinetic parameters of cyclosporine (CsA) were determined in 23 kidney transplant recipients and 19 children with nephrotic syndrome, after intravenous and oral administration. Cyclosporine 34-46 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 48-51 8453556-1 1993 BACKGROUND: Cyclosporine (cyclosporin A, CSA) prolongs the survival of transplanted organs by reducing the transcription of cytokines, especially interleukin-2, that are thought to mediate T-cell expansion and subsequent graft rejection. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 41-44 8003314-1 1994 Cyclosporin A (CSA) is an immunosuppressive agent that has provided new approaches in transplantation medicine and in the treatment of autoimmune diseases. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 7683633-2 1993 The T-cell-targeting immunosuppressants, FK506 and cyclosporin A (CsA), suppressed proliferation of the HAM/TSP-derived T-cell lines, H89-59, H89-79 and H109. Cyclosporine 51-64 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 7507316-1 1993 The cyclic peptide Cyclosporine A (CsA) is best known as the immunosuppressive drug which has revolutionized organ transplantation. Cyclosporine 35-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 19-33 8400080-1 1993 The isolated perfused rat kidney (IPK) was used to study the acute effects of cyclosporin A (CsA) and its metabolites (M1, M17, M18, M21 and M-COOH). Cyclosporine 78-91 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 93-96 8400080-9 1993 Cyclosporine metabolite levels in patient blood often greatly exceed levels of the parent drug; these studies suggest that the metabolites may contribute significantly to CsA nephrotoxicity in patients. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 171-174 8100562-1 1993 The synergistic effect of MRK-16, a monoclonal antibody against P-glycoprotein, and cyclosporin A (CsA) on the modulation of vincristine resistance was studied by isobologram analysis in three different, highly multidrug-resistant tumor cells. Cyclosporine 99-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 84-97 8489193-1 1993 Cyclosporine (CsA) has played a major role in the development of organ transplantation. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 8445424-1 1993 PURPOSE: We investigated if graft-versus-host disease (GVHD), which is associated with an antitumor effect, could be induced in women with advanced breast cancer by treatment with cyclosporine (CSA) following reinfusion of purged autologous marrow after treatment with high-dose chemotherapy and defined the toxicities of this approach. Cyclosporine 180-192 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 194-197 8081782-1 1993 Cyclosporine A (CSA) is the standard immunosuppressive agent used in human cardiac transplantation to prevent rejection; however, adverse side effects have been reported at therapeutic doses. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 8293040-1 1993 Use of the immunosuppressant drug cyclosporine A (CSA) has resulted in improved renal graft survival. Cyclosporine 34-48 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 50-53 1348520-2 1992 Previous studies have shown that proliferation of peripheral blood T cells involving the CD28 pathway is associated with cyclosporine A (CsA) resistant IL-2 gene expression. Cyclosporine 121-135 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 137-140 1493564-1 1992 Cyclosporine (CsA) has played a major role in the development of organ transplantation. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 1643712-1 1992 Cyclosporin A (CsA) is currently the most selective immunosuppressant used clinically to prevent organ rejection after transplantation. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 8302414-1 1993 We studied 20 kidney transplant recipients who had received Sandimmune cyclosporine A (CSA) capsules for an average of 7.9 months at a mean dose of 312 mg/day. Cyclosporine 71-85 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 1403040-1 1992 PURPOSE: To determine the maximum-tolerated dose (MTD) of cyclosporine (CsA) infusion administered with etoposide for 3 days in patients with cancer. Cyclosporine 58-70 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 72-75 1403041-1 1992 PURPOSE: To determine the effects of high-dose cyclosporine (CsA) infusion on the pharmacokinetics of etoposide in patients with cancer. Cyclosporine 47-59 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 61-64 1346494-1 1992 Cyclosporin A (CsA), a cyclic peptide of 11 amino acids isolated from the fungus Tolypoclodium inflatum Gams, is the principle drug used for immunosuppression in organ transplant patients. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 1372027-1 1992 Cyclosporine (CSA) decreases lymphokine synthesis and keratinocyte proliferation in vitro, but its in vivo mechanism of action in treating recalcitrant psoriasis is incompletely understood. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 14621852-3 1992 The use of cyclosporine (CSA) means new problems for the pregnant women and the fetus: the risk of congenital abnormalities, fetal growth retardation, hepato- and nephrotoxicity. Cyclosporine 11-23 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 25-28 1915562-1 1991 Cyclosporin A (CSA) is an immunosuppressive drug, which blocks selective activation pathways in T and B cells. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 1717376-1 1991 Cyclosporin (CsA) and FK-506 are structurally distinct fungal metabolites, which exert powerful inhibitory effects on CD4+ T (helper) cell activation and on the secretion of interleukin-2 (IL-2) and other cytokines, including various cell growth factors and interferon-gamma. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 1755407-1 1991 To clarify the distribution and the kinetics of ciclosporin (CSA) in the lymphatic system, we measured the CSA level of the lymph from the thoracic duct drainage (TDD) and that of the peripheral blood after oral or intravenous administration of CSA in 13 TDD pretreated patients. Cyclosporine 48-59 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 61-64 2054356-1 1991 Cyclosporin A (CsA), a potent immunosuppressant, is known to bind with high specificity to cyclophilin (CyP), a 17.7 kDa protein with peptidyl-prolyl isomerase activity. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 2056124-3 1991 Infusion of cyclosporine (CSA) hemodynamically parallels ET action, and knowing that CSA effects EC, we hypothesize that the vasoconstrictive effects of CSA are a result of ET synthesis by EC. Cyclosporine 12-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 1827045-8 1991 The acquisition of NK1.1, B220, and lytic activity by this triple-negative subset was readily inhibited by cyclosporine A (CSA). Cyclosporine 107-121 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 123-126 2031507-1 1991 Cyclosporin A (CSA) is an immunosuppressive agent that in experimental models has antiproliferative activity against colon cancer and other human neoplasms. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 1854886-3 1991 Treatment of this disease with cyclosporin-A (CSA) therefore appears to be sensible. Cyclosporine 31-44 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 46-49 2060129-1 1991 Cyclosporine (CsA) is extensively metabolized, with over 14 metabolites having been characterized to date. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 2029952-4 1991 Ten patients (11 pregnancies) were treated with ciclosporin A (CsA). Cyclosporine 63-66 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 48-61 2060136-1 1991 The immunosuppressive action of cyclosporine (CsA) in vivo is thought to primarily involve its inhibitory effect on lymphokine production by T lymphocytes. Cyclosporine 32-44 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 46-49 1985948-2 1991 Peptidyl-prolyl cis-trans-isomerase and the cyclosporin A (CsA)-binding protein cyclophilin are identical, and peptidyl-prolyl cis-trans-isomerase activity is inhibited by the immunosuppressive drug CsA in vitro. Cyclosporine 44-57 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 59-62 1903312-4 1991 Whereas the PRCA repeatedly responded to immunosuppression with high-dose cyclosporin A (CSA) and CSA plus plasmapheresis, IFN antibody production continued during treatment with cyclophosphamide and CSA. Cyclosporine 74-87 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 89-92 2250411-4 1990 The graft volume at 2-3 months after transplantation was smaller (215.9 +/- 30.9 ml, mean +/- SD) in patients who received small amounts of ciclosporin A (CsA) together with azathioprine and steroid than that (270.9 +/- 75.0 ml) in those treated by conventional immunosuppression. Cyclosporine 155-158 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 140-153 2064787-1 1991 The kinetics and extent of uptake of cyclosporin (CSA) in various strata of human cadaver skin upon topical application of several CSA formulations were determined by in vitro diffusion cell experiments. Cyclosporine 37-48 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 50-53 2064787-1 1991 The kinetics and extent of uptake of cyclosporin (CSA) in various strata of human cadaver skin upon topical application of several CSA formulations were determined by in vitro diffusion cell experiments. Cyclosporine 37-48 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 131-134 2076903-2 1990 Increasing knowledge concerning the action of cytokines on the permeability of the vascular barrier, and the possibility to suppress their production with ciclosporin A (CsA), especially of the cytokine interleukin-2, made its therapeutic use for the treatment of NS reasonable. Cyclosporine 170-173 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 155-168 1725322-1 1991 Cyclosporine A (CSA) stimulated endothelin secretion by a cultured renal epithelial cell line, LLC-PK1. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 2094690-1 1990 Factors which can account for the poor correlation between whole blood and plasma Cyclosporine (CsA) levels in patients on CsA prophylaxis are evaluated. Cyclosporine 82-94 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 96-99 2094690-1 1990 Factors which can account for the poor correlation between whole blood and plasma Cyclosporine (CsA) levels in patients on CsA prophylaxis are evaluated. Cyclosporine 82-94 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 123-126 1724618-2 1990 The cyclic peptides cyclosporin A (CSA) and gramicidin-S (GRS) are shown to bind CaM and inhibit 3",5"-cyclic nucleotide phosphodiesterase (PDE) in a calcium-dependent manner. Cyclosporine 20-33 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 35-38 1690774-2 1990 Cyclosporin A (CSA) inhibits IgE receptor-mediated exocytosis from rat basophilic leukemia (RBL) cells and human peripheral blood basophils in a dose-dependent manner over the therapeutic range of CSA concentrations achieved in vivo. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 1971531-5 1990 Cyclosporine (CsA) prevented diC8 and ionomycin-induced expression of IL-2, IFN-gamma, and H-ras genes. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 2374050-3 1990 Evidence accumulates suggesting cyclosporine (CSA) acts as a potent vasoconstricting agent and that antihypertensive medications such as calcium channel blocking agents may offer protection from this effect. Cyclosporine 32-44 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 46-49 1690774-2 1990 Cyclosporin A (CSA) inhibits IgE receptor-mediated exocytosis from rat basophilic leukemia (RBL) cells and human peripheral blood basophils in a dose-dependent manner over the therapeutic range of CSA concentrations achieved in vivo. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 197-200 2113225-1 1990 We analysed our population of renal transplant recipients treated with cyclosporin (CsA) and prednisolone with respect to clinically evident de novo malignancies. Cyclosporine 71-82 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 84-87 2108610-1 1990 For the purpose to establish the reliability of SRCA using clinical materials, a histological assessment under the suppression of host reaction was introduced; 1) for the immune suppression cyclosporin A (CsA) was used, 2) to overcome the heterogeneity of fragments, the numbers of implants were increased to ten per group (two pieces/kidney), 3) time flame was 6 days as original, 4) the amounts of drugs were essentially similar to those of Bogden"s original method. Cyclosporine 190-203 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 205-208 2311397-0 1990 Therapeutic drug monitoring of cyclosporine (CSA). Cyclosporine 31-43 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 45-48 1968924-3 1990 Cyclosporine A (CsA) inhibits T lymphocyte activation in vitro by blocking at a pretranslational level the production of IL-2 and other cytokines. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 11390729-1 2001 BACKGROUND: The new cyclosporin (CsA) formulation, Neoral, has different pharmacokinetics compared with Sandimmune (SIM). Cyclosporine 20-31 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 33-36 35606904-1 2022 Despite the common use of cyclosporine (CsA) for acute graft-versus-host disease (aGVHD) prophylaxis following allogeneic stem cell transplant, the optimal CsA trough target remains unknown. Cyclosporine 26-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 40-43 33201059-1 2021 PURPOSE: To compare efficiency and tolerance between topical 0.5% cyclosporine A (CSA) and fluorometholone (FML) for subepithelial infiltrates (SEI) complicating epidemic keratoconjunctivitis. Cyclosporine 66-80 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 82-85 35143644-2 2022 We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT. Cyclosporine 157-171 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 173-176 35143644-2 2022 We performed a prospective randomized, multicenter, phase III trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse free survival (GRFS) as compared to the combination of CsA and mycophenolic acid (MPA) after non-myeloablative (NMA) matched related and unrelated peripheral blood alloHSCT. Cyclosporine 157-171 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 314-317 2797718-1 1989 Cyclosporine (cyclosporin A, CsA) is a selective T-cell immunosuppressant that works primarily through inhibition of both antigen presentation and lymphokine production. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 29-32 2789931-1 1989 The effects of four Ca2+ channel antagonists on the metabolism of cyclosporine (CsA) by human liver microsomes (n = 4) in vitro have been examined. Cyclosporine 66-78 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 80-83 2676910-1 1989 Controlled double-blind studies have demonstrated the efficacy of 14 mg/kg per day cyclosporin A (CsA) in patients with severe psoriasis. Cyclosporine 83-96 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 98-101 2674381-2 1989 Two patients had evidence of extremely erratic absorption of the cyclosporine (CSA) used for immunosuppression. Cyclosporine 65-77 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 79-82 2798309-1 1989 The currently available intravenous dosage form of cyclosporine (CSA), Sandimmune I.V., contains the vehicle, Cremophor EL, which has been implicated in producing anaphylactic reactions in man and animals. Cyclosporine 51-63 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 65-68 2522829-1 1989 Two novel models of activation of human peripheral blood quiescent T-cells (T-cells) were utilized herein as probes to analyze the mechanisms and to locate the site of action of cyclosporine (CsA) in the T-cell activation pathway. Cyclosporine 178-190 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 192-195 2735909-4 1989 From 0.001 to 1 microgram/ml, CsA dose-dependently inhibited lipopolysaccharide (LPS) induced secreted bioactivity; at doses above 10 micrograms/ml CSA was directly toxic to CFA-MO. Cyclosporine 30-33 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 148-151 2784875-2 1989 While cyclosporine (CsA) present during the macrophage-T cell coculture inhibited antigen presentation effectively, pretreatment (2 hr) of macrophages with the drug also caused marked inhibition regardless of the antigen concentration and order of drug/antigen addition. Cyclosporine 6-18 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 20-23 2784875-5 1989 Cyclosporine demonstrated saturable binding to macrophages suggesting the existence of CsA-binding sites. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 2647858-0 1989 Antibodies to cyclosporine A (CsA) by a novel route and their use to monitor cyclosporine levels by radioimmunoassay (RIA). Cyclosporine 14-26 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 30-33 2647858-1 1989 Anti-cyclosporine antibodies were generated in rabbits, using an antigen derived from CsA. Cyclosporine 5-17 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 86-89 2647858-3 1989 In the presence of CsA, photolysis of BBa results in hydrogen abstraction and random insertion into the cyclosporine molecule, generating a population of CsA with carboxyl groups at various positions. Cyclosporine 104-116 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 19-22 2647858-3 1989 In the presence of CsA, photolysis of BBa results in hydrogen abstraction and random insertion into the cyclosporine molecule, generating a population of CsA with carboxyl groups at various positions. Cyclosporine 104-116 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 154-157 2468619-1 1989 Cyclosporin A (CsA) is now widely used in the prevention/treatment of graft rejection and in the treatment of some human inflammatory diseases. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 2925842-1 1989 Cyclosporine A (CsA) has been used in putative autoimmune diseases after sensitization to unknown antigens. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 2652679-0 1989 Effective prophylaxis of early post-transplant urinary tract infections (UTI) in the cyclosporine (CSA) era. Cyclosporine 85-97 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 99-102 3046689-1 1988 Between 1982 and 1986 51 patients were treated with ciclosporin a (CSA) to prevent graft versus host disease (GvHD) after bone marrow transplantation (BMT). Cyclosporine 52-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 67-70 3242657-1 1988 It is demonstrated that cyclosporine (CsA), a novel fungal-derived immunosuppressive agent, attenuates naloxone-precipitated morphine withdrawal in an unusual dose-dependent manner following direct intracerebroventricular (icv) administration. Cyclosporine 24-36 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 38-41 2588745-1 1989 The aim of the study was to investigate the influence of a pretreatment of the heart donor with cyclosporin (CsA) at 25 or 50 mg kg BW on day -1 on survival time of rat heart allografts in a donor-recipient combination that was different at their major histocompatibility complex (MHC). Cyclosporine 96-107 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 109-112 3262237-1 1988 Cyclosporine A (CsA) is an important immunosuppressive drug that is widely used in transplantation medicine. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 3056547-6 1988 Treatment of chronic GVHD in this model has shown thalidomide to be better tolerated and more successful than cyclosporine (CSA) or prednisone plus azathioprine. Cyclosporine 110-122 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 124-127 3278422-1 1988 Low-dose cyclosporine (CsA) plus prednisone for induction and maintenance immunosuppression were used in 106 consecutive cadaveric renal transplants. Cyclosporine 9-21 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 23-26 3136044-1 1988 Potential side-effects of the immunosuppressive drug cyclosporine (also cyclosporin A, CsA) on ovarian endocrine function have been investigated using granulosa cells isolated from immature estrogen-primed rats and cultured in a chemically defined medium. Cyclosporine 53-65 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 87-90 2896111-1 1988 The immunosuppressive drug cyclosporin A (CsA) inhibits mixed lymphocyte responses, blocks the generation of cytotoxic T lymphocytes, and inhibits the T lymphocyte proliferative response stimulated by polyclonal activators such as phytohemagglutinin (PHA). Cyclosporine 27-40 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 42-45 3172640-1 1988 A major problem in cyclosporine A (CsA) therapy is its nephrotoxicity, characterized by a marked fall in glomerular filtration rate (GFR). Cyclosporine 19-33 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 35-38 3045721-2 1988 In this study, kidney function was measured simultaneously and continuously for 6.6 h with engymetry, after application of a 12 h therapy dose of Cyclosporine A (CsA) of 4.0 +/- 1.8 mg per kg bodyweight (bw). Cyclosporine 146-160 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 162-165 3201530-1 1988 The evaluation of a radioimmunoassay (RIA) for the monitoring of cyclosporine (CSA) that utilizes a monoclonal antibody specific for the parent compound is described. Cyclosporine 65-77 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 79-82 3132645-1 1988 We have developed a simple method of sample collection which allows the measurement of cyclosporin (CsA) to be made from blood obtained from a finger stab and collected onto filter paper. Cyclosporine 87-98 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 100-103 3544378-1 1987 Nephrotoxicity and cost are the major problems in the use of cyclosporine (CsA) in renal transplantation. Cyclosporine 61-73 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 75-78 3319309-1 1987 We report seven cases out of eight reversible raises (350% of mean increase) of cyclosporine (CsA) plasma levels in patients receiving the new calcium channel blocker nicardipine (Loxen-Sandoz) and CsA after renal transplantation. Cyclosporine 80-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 3319309-1 1987 We report seven cases out of eight reversible raises (350% of mean increase) of cyclosporine (CsA) plasma levels in patients receiving the new calcium channel blocker nicardipine (Loxen-Sandoz) and CsA after renal transplantation. Cyclosporine 80-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 198-201 2439348-1 1987 Cyclosporin A (CsA) produced dose-dependent membrane depolarization of human peripheral blood lymphocytes. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 3495054-1 1987 Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 3544387-1 1987 High-performance thin-layer chromatography (HPTLC) has advantages for the analysis of cyclosporine (CsA) and its metabolites in peripheral blood not shared by the radioimmunoassay (RIA) or high-performance liquid chromatography (HPLC) methods. Cyclosporine 86-98 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 100-103 3114680-2 1987 Cyclosporin (CsA) was the sole immunosuppressive in 70% of the cases, and azathioprine-prednisolone in 30%. Cyclosporine 0-11 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 13-16 3526606-1 1986 Endothelial injury associated with cyclosporine (CSA) therapy in the absence of rejection has resulted in irreversible intrarenal allograft thrombosis and transplant loss. Cyclosporine 35-47 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52 3306668-8 1987 Graft functional survival rates were significantly higher (p less than 0.05) in recipients who received azathioprine (AZA) and cyclosporine (CSA) in combination (n = 408) than in those who received CSA without azathioprine (n = 262) or AZA without cyclosporine, (n = 56), with 1 year graft functional survival rates of 47, 38, and 34%, respectively. Cyclosporine 127-139 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 141-144 3769526-1 1986 Cyclosporin A (CsA) was administered to chicks of the Smyth delayed-amelanotic (SDA) line from day of hatch to 4, 8 or 12 weeks of age. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 3160143-2 1985 Human monocytes (M phi) preexposed to cyclosporine (CsA) concentrations ranging between 1.0 and 10.0 micrograms/ml were impaired in their ability to stimulate autologous and allogeneic mixed lymphocyte reactions (MLR) when they were compared with control M phi unexposed to CsA. Cyclosporine 38-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 52-55 3490123-0 1986 Inhibition of T cell cytotoxicity by cyclosporine (CSA), adenosine (Ado) and an inhibitor of adenosine deaminase (ADA). Cyclosporine 37-49 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 51-54 2942335-1 1986 Cyclosporine (CsA) is a novel immunosuppressive agent currently used clinically, to prevent rejection of solid organ allografts and to prevent graft-vs.-host disease. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 3907030-1 1985 Cyclosporine (CsA) dose adjustment after renal transplantation is generally based on serum, plasma, or whole-blood trough level values. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 3519782-1 1986 The immunosuppressant cyclosporine (CSA) has shown usefulness in both animal and human transplantation. Cyclosporine 22-34 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 36-39 3003975-1 1986 Cyclosporine (CsA), a potent immunosuppressant for the prevention of transplant rejection, modulates T lymphocyte activation by blocking antigen stimulation and the production of interleukin-2. Cyclosporine 0-12 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 14-17 3003976-1 1986 The effectiveness of cyclosporine (CsA) as immunosuppressive agent in human kidney graft rejection is well established. Cyclosporine 21-33 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 35-38 3914572-1 1985 The outcome of patients with acute renal failure following cadaveric renal transplant has been evaluated in a prospective, controlled trial, comparing treatment with cyclosporine (CSA) to prednisone, azathioprine, and antilymphocyte globulin (AZA). Cyclosporine 166-178 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 180-183 3160143-2 1985 Human monocytes (M phi) preexposed to cyclosporine (CsA) concentrations ranging between 1.0 and 10.0 micrograms/ml were impaired in their ability to stimulate autologous and allogeneic mixed lymphocyte reactions (MLR) when they were compared with control M phi unexposed to CsA. Cyclosporine 38-50 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 274-277 6256660-1 1981 Cyclosporin A (CSA) is a fungal metabolite which exerts profound effects on the immune system and has potential as a selective immuno-suppressive agent. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 6237152-1 1984 LEW rat recipients of (LEW X BN)F1 strain heterotopic cardiac transplants treated with cyclosporine A (CsA) (15 mg/kg/day intramuscularly, 7 days) retain grafts indefinitely despite drug withdrawal. Cyclosporine 87-101 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 103-106 6437025-1 1984 Human monocytes (M phi) exposed to 0.5-20 micrograms/ml of cyclosporine (CsA) produced levels of prostaglandins of the E series (PGE) that were 2-3-fold greater than control M phi cultured in medium alone. Cyclosporine 59-71 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 73-76 6196379-1 1983 To probe the mechanism of suppressor T cell generation in man, we have carried out mixed leukocyte reactions (MLR) in the presence of cyclosporin (CsA), a fungal metabolite which prevents the generation of cytotoxic lymphocytes while permitting activation of suppressor cells. Cyclosporine 134-145 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 147-150 6332315-1 1984 Cyclosporin A (CsA) is a potent immunosuppressive agent, now gaining wide application in human organ transplantation. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 6863928-1 1983 The purpose of this investigation was to identify and characterize a possible plasma membrane receptor for cyclosporine (CsA) on human lymphoid cells. Cyclosporine 107-119 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 121-124 33896035-2 2021 The aim of this study is analyzing the results of switching cyclosporine (CSA) to tacrolimus because of acute GvHD, engraftment syndrome (ES), persistent low level of CSA, or various CSA-associated adverse events in the first 100 days of pediatric HSCT. Cyclosporine 60-72 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 74-77 34041632-2 2021 Recently, the drugs most commonly used for the treatment of psoriasis include methotrexate (MTX), cyclosporine (CsA), acitretin, dexamethasone, and salicylic acid. Cyclosporine 98-110 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 112-115 33023428-1 2021 Cyclosporine A (CsA) is a cyclic undecapeptide with strong immunosuppressive potency. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 33160221-1 2021 Measuring cyclosporine A (CsA), an immunosuppressive drug used to prevent heart transplant rejection, concentrations in myocardial biopsies might be more informative than its measurement in whole blood. Cyclosporine 10-24 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 26-29 33794964-1 2021 BACKGROUND: To evaluate cyclosporine A (CSA)-related neurotoxicity after haploidentical hematopoietic stem cell transplantation (HID-HSCT) in children with hematopathy. Cyclosporine 24-38 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 40-43 33440765-3 2021 The most common mechanism of mPT is based on the opening of a cyclosporine A (CSA)-sensitive protein channel in the inner membrane. Cyclosporine 62-76 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 78-81 31911259-2 2020 We analyzed AKI in adult myeloablative CBT recipients who underwent transplantation from 2006 to 2017 for hematologic malignancies using cyclosporine A (CSA)/mycophenolate mofetil immunosuppression. Cyclosporine 137-151 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 153-156 32894914-9 2020 %CSA(5-10) of three groups were (0.63+-0.15)%, (0.84+-0.18)%, and (0.85+-0.25)% (P<0.01), respectively; %CSA(<5) and %CSA(5-10) of medium-high risk group were lower than low-risk group and control group. Cyclosporine 1-4 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 105-111 31243130-1 2019 Previously, the cyclophilin inhibitors cyclosporine (CsA) and alisporivir (ALV) were shown to inhibit the replication of diverse RNA viruses, including arteriviruses and coronaviruses, which both belong to the order Nidovirales In this study, we aimed to identify arterivirus proteins involved in the mode of action of cyclophilin inhibitors and to investigate how these compounds inhibit arterivirus RNA synthesis in the infected cell. Cyclosporine 39-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 31283681-1 2020 BACKGROUND: After patients receive hematopoietic stem cell transplantation (HSCT), both cyclosporine (CsA) and tacrolimus (TAC) in combination with methotrexate (MTX) are recommended as the standard prophylaxis strategy for graft-versus-host disease (GVHD) by the European Group of Blood and Marrow Transplantation (EBMT). Cyclosporine 88-100 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 102-105 32030447-1 2020 For patients with pure red cell aplasia (PRCA), cyclosporine (CsA) is the first line therapy. Cyclosporine 48-60 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 62-65 31597813-1 2019 Phenobarbital (PB) decreases the cyclosporine (CsA) blood level in humans. Cyclosporine 33-45 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 47-50 31646979-1 2019 BACKGROUND: The purpose of this study was to determine efficacy and safety of cyclosporine A (CsA) for patients with steroid-resistant nephrotic syndrome (SRNS). Cyclosporine 78-92 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 94-97 31517988-1 2019 BACKGROUND: Topical cyclosporine A (also known as ciclosporin A) (CsA) is an anti-inflammatory that has been widely used to treat inflammatory ocular surface diseases. Cyclosporine 20-34 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 31517988-1 2019 BACKGROUND: Topical cyclosporine A (also known as ciclosporin A) (CsA) is an anti-inflammatory that has been widely used to treat inflammatory ocular surface diseases. Cyclosporine 50-63 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 66-69 31243130-8 2019 Previously, the cyclophilin inhibitors cyclosporine (CsA) and alisporivir (ALV) were shown to inhibit the replication of diverse nidoviruses (both arteriviruses and coronaviruses), and they may thus represent a class of pan-nidovirus inhibitors. Cyclosporine 39-51 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 53-56 30713473-1 2018 Cyclosporin A (CsA) is known to have an immunosuppressive action. Cyclosporine 0-13 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 15-18 30977158-1 2019 OBJECTIVE: Immunosuppressive therapy (IST) with horse anti-thymocyte globulin (hATG) and cyclosporine (CsA) is considered one of the first-line therapies in patients (pts) with acquired aplastic anemia (AA). Cyclosporine 89-101 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 103-106 30542943-2 2019 Prophylaxis with cyclosporine A (CsA) is the backbone of GvHD prevention. Cyclosporine 17-31 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 33-36 29960018-1 2018 Cyclosporine A (CsA) is a widely used immunosuppressive agent that greatly reduces the rates of kidney-, heart-, and liver-transplant rejection. Cyclosporine 0-14 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 16-19 30401391-2 2018 In this study, we compared renal function after heart transplantation (HT) under EVR with cyclosporine (CSA) or tacrolimus (TAC). Cyclosporine 90-102 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 104-107 29704799-1 2018 Overestimation of immunoassays for cyclosporine (CsA) and tacrolimus (TAC) analysis in human whole blood is a problem. Cyclosporine 35-47 ERCC excision repair 8, CSA ubiquitin ligase complex subunit Homo sapiens 49-52